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The reeler mutant mouse (rl/rl) has been proposed to be a behavioral model of 
schizophrenia. The purpose of the current research was to study the effects of the 
antipsychotic, risperidone, on the rl/rl, because if the rl/rl models schizophrenia, then 
risperidone should improve its cognitive, emotional, and sensorimotor gating deficits. 
Wildtype (+/+), rl/rl, and hybrid (+/rl) mice were tested in open field, light-dark, PPI, 
nose poke, and passive avoidance after receiving 1.0 mg/kg of risperidone or vehicle via 
oral gavage for 3 weeks, and dosing continued throughout testing. Overall, there were 
few significant effects of the drug, but when it did have an effect on the rl/rl, it worsened 
its performance, and so the results could not support the hypothesis. Future research 
should re-examine the rl/rl in a wider battery of behavioral tests in order to determine if 
the rl/rl models another disorder, such as autism. 
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CHAPTER I 
 
INTRODUCTION  
 
 
Given the complexity of human psychiatric disorders, it is unlikely that any one 
animal could ever model all of the symptoms associated with such a disorder (Joober, 
Boska, Benkelfat, & Rouleau, 2002; Crawley, 2000; Lipska & Weinberger, 2000; van 
den Buuse, Garner, Gogos, & Kusljic, 2005). However, animals are nonetheless useful in 
the study of human diseases, because they allow for more controlled study of specific 
aspects of a disorder than can typically be obtained in studies with humans (Crawley, 
2000). The goals of using animals in studying human conditions are to test hypotheses 
about the mechanisms of the disease and to predict human responses to treatment 
(Crawley, 2000). In that regard, then, animals can represent a disorder on different levels, 
depending on whether one is interested in studying phenomenology, etiology (such as a 
genetic predisposition to a disorder), or treatment response (Lipska & Weinberger, 2000). 
According to Crawley (2000), there are several criteria that a potential animal 
model of a disorder must satisfy in order to be considered a good model (Table 1). As can 
be seen from the table, an animal’s validity as a model of a disorder increases with the 
number of ways it replicates aspects of a disease. However, it must be remembered that 
psychological disorders involve neural circuitry and emotions that are most likely unique 
to humans, and so an animal’s utility as a model must not be overstated (Crawley, 2000).  
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Table 1 
Criteria for Good Animal Models of Human Psychiatric Diseases 
________________________________________________________________________ 
 
1. Replicates at least one symptom of the human disease 
2. Responds to treatments that are effective in the human disease 
3. Is unaffected by treatments that are ineffective in the human disease 
4. Conceptual analogy to the etiology of the human disease is desirable but not 
necessary 
5. Conceptual analogy to multiple components of the human disease is desirable: 
a. Behavioral symptoms 
b. Neuroanatomical abnormalities 
c. Neurochemical abnormalities 
d. Temporal progression 
e. Precipitating event 
________________________________________________________________________ 
Source: Crawley (2000).  
 
Schizophrenia is a complex psychological disorder comprised of a broad 
constellation of abnormalities. Although much has been learned about the behavioral and 
biological abnormalities of schizophrenia, what still remain largely unclear are its origins 
and development over time (Wong & Van Tol, 2003). Given the overwhelming personal 
and societal costs and burdens of the illness, it seems prudent to further scientific 
understanding of the disease in order to increase the effectiveness of treatment, to 
increase prediction of who is at risk to develop the disorder, and to improve prevention in 
those found to be at risk. Animals that meet any of the criteria above for schizophrenia 
could be useful in advancing our knowledge of this disease. 
The positive symptoms listed in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revised (DSM-
IV-TR; 2000) are the most recognizable symptoms of the disease, and include 
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hallucinations, delusions, and disordered thought. However, it is difficult to imagine how 
one could induce observable hallucinations or delusions in an animal (Lipska & 
Weinberger, 2000; Crawley, 2000), and so animal models of schizophrenia have tended 
to focus on schizophrenia’s other symptoms, such as its negative symptoms and cognitive 
deficits, which are also more common and chronic among those with schizophrenia than 
are the positive symptoms (Le Pen, Grottick, Higgins, & Moreau, 2003). Negative 
symptoms include flattened affect/abnormal emotionality, alogia, and anhedonia (DSM-
IV-TR). Cognitive deficits include executive functioning deficits, impaired verbal and 
nonverbal working memory, and inattention (Conklin, Curtis, Calkins, & Iacono, 2005; 
Fitzgerald, Lucas, Redoblado, Winter, et al., 2004; Gooding & Tallent, 2004; Silver, 
Feldman, Bilker, & Gur, 2003).  
Impaired sensorimotor gating is another common feature of schizophrenia that is 
easily measured in animals (e.g., van den Buuse, Garner, & Koch, 2003). Sensorimotor 
gating refers to the brain’s filtering out of irrelevant stimuli in order to prevent sensory 
over-stimulation of higher brain functions (Oranje, van Oel, Gispen-de Wied, Verbaten, 
& Kahn, 2002). The most common way to measure sensorimotor gating is by examining 
the prepulse inhibition of the acoustic startle response (PPI) (Geyer, Krebs-Thomson, 
Braff, & Swerdlow, 2001). PPI measures the individual’s unlearned, reflexive 
suppression of a response to a startling stimulus when that stimulus is preceded by a non-
startling one (e.g., Geyer et al., 2001; Kumari & Sharma, 2002; Braff, Geyer, & 
Swerdlow, 2001). Schizophrenia patients were first reported to have deficits in PPI 
compared to controls by Braff, Stone, Callaway, Geyer, et al. in 1978, and since then, 
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numerous researchers have found deficits in PPI in schizophrenia patients (Parwani, 
Duncan, Bartlett, Madonick, et al., 2000; Meincke, Mörth, Voβ, Thelen, et al., 2004; 
Ludewig, Geyer, & Vollenweider, 2003; Mackeprang, Kristiansen, & Glenthoj, 2002).  
In the past decade, the results of a post-mortem study indicated that schizophrenia 
patients have about a 50% decreased expression of both protein and mRNA reelin in the 
brain compared to non-schizophrenic controls (Impagnatiello, Guidotti, Pesold, Dwivedi, 
et al., 1998). Reelin is a key signaling protein that plays a crucial role in prenatal 
corticogenesis (Teuting, Costa, Dwivedi, Guidotti, et al., 1999). In the absence of reelin, 
new neurons are positioned below layers of older neurons instead of developing in the 
“inside-out” manner characteristic of normative cortical development (Teuting et al., 
1999; Luque, Morante-Oria, & Fairén, 2003). Because of the reelin deficiency found in 
schizophrenia patients, mice with similar reelin deficiencies have been hypothesized to be 
models of schizophrenia (Teuting et al., 1999; Qiu, Korwek, Pratt-Davis, Peters, et al., 
2006). 
The heterozygous reeler mouse (+/rl), which has one copy of the reelin gene and 
therefore produces about 50% of normal reelin levels compared to wildtype (+/+) 
controls, was first hypothesized to model schizophrenia by Teuting et al. (1999). The +/rl 
was reported to have deficient PPI compared to +/+, and displayed greater anxiety on an 
elevated plus maze (although there were data from four male mice only on this test). 
Because such emotional and cognitive deficits are also found in people who have 
schizophrenia, they concluded that the +/rl was a model of schizophrenia. Most recently, 
Qiu et al. (2006) also reported that the +/rl is a model of schizophrenia. They arrived at 
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their conclusion based on the results of one test of contextual fear conditioning, and on a 
significant difference in PPI (for which they did not report their methods) at only one 
prepulse intensity.  In the same report, however, they found no differences between the 
two genotypes in overall activity, thermal nociception, startle responding, anxiety-like 
behaviors, cued freezing, and spatial learning.  
However, the results of three separate studies fail to confirm those findings of 
schizophrenia-relevant abnormalities in the behavioral phenotype of +/rl mice  (Salinger, 
Ladrow, & Wheeler, 2003; Groves, O’Meara, Handford, Smith, et al., 2003; Podhorna & 
Didriksen, 2004). Salinger et al. (2003) reported that +/rl and +/+ mice were 
indistinguishable from each other on a wide variety of behavioral tests, including PPI, 
open field, light/dark, and nose-poke (a test of cognitive functioning). Groves et al. 
(2003) studied male +/rl and +/+ mice and found no differences between them in PPI or 
locomotor activity. In 2004, Podhorna and Didriksen also reported the results of an 
experiment designed to investigate phenotypic differences between +/rl and +/+ mice. In 
accord with Salinger et al. (2003) and Groves et al. (2003), they concluded that +/rl mice 
were not distinguishable from +/+, and further stated that the +/rl may not be a good 
model of schizophrenia.  
Unlike Teuting et al. (1999), Groves et al. (2003), and Podhorna and Didriksen 
(2004), however, Salinger et al. (2003) also studied the homozygous reeler mutant mouse 
(rl/rl) in addition to the +/rl and +/+ and reported that the rl/rl displayed significant 
behavioral abnormalities compared to the other two genotypes. Furthermore, the 
abnormalities displayed by this mouse suggested that it and not the +/rl might be a more 
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appropriate model of schizophrenia. The rl/rl was found to have significant deficits in 
PPI, consistent with findings from the human schizophrenia literature (Braff et al., 1978; 
Parwani, et al., 2000; Meincke, et al., 2004; Ludewig, et al., 2003; Mackeprang, et al., 
2002). The rl/rl was also shown to exhibit abnormal emotional behaviors, including a 
long latency to enter the dark half of the test chamber in the light/dark task, fewer boli in 
the open field, and an abnormal lack of preference to remain on perimeter areas of the 
open field during exploration (see Crawley, 2000 for a more detailed description of tests 
used to measure emotionality in mice). The rl/rl displayed significant cognitive deficits 
compared to +/rl and +/+ mice as well, including deficits in working memory. Because 
of the shared behavioral deficits and deficiencies in reelin production between rl/rl mice 
and humans with schizophrenia, the rl/rl was hypothesized to model schizophrenia, and is 
the genotype under investigation here. Because of the conflicting findings reported in the 
literature on the +/rl, however, +/rl mice were included in this experiment in order to 
determine if their behavioral phenotype would confirm Salinger et al.’s (2003) previous 
findings. 
The focus on reelin-deficient mice in this research is not meant to imply that other 
models of schizophrenia do not exist. However, the rl/rl mouse is unique in that, not only 
are its genetic and behavioral abnormalities naturally occurring instead of experimentally 
induced, but also that it shows behavioral abnormalities across multiple domains similar 
to those found in schizophrenia, instead of showing deficits only in one area, such as PPI 
or hyperactivity. Other models of schizophrenia include (but are in no way limited to) 
rats that have received neonatal ventral hippocampal lesions and show deficits in 
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cognition and social interactions in adulthood (e.g., Lipska, 2004); rodents that have 
drug-induced hyperactivity or drug-disrupted PPI (for a review, see van den Buuse et al., 
2005); and mice with experimentally-induced genetic mutations, such as the chakragati 
mouse, which shows abnormal social interactions (e.g., Torres, Hallas, Vernace, Jones, et 
al., 2004).Because the rl/rl has naturally-occurring deficits, it may more closely model 
the development of the disorder in humans, which would satisfy Crawley’s (2000) 
etiology criterion, shown in Table 1.
Table 2 shows the ways in which rl/rl mice have already been found to meet 
several of Crawley’s (2000) requirements as a good animal model of schizophrenia. As 
mentioned above, the rl/rl has been shown to have deficits in PPI, emotionality, and 
cognition by Salinger et al. (2003), and also has been found by other research to have 
neurochemical (Curran & D’Arcangelo, 1998) and neuroanatomical (D’Arcangelo & 
Curran, 1998) abnormalities, similar to those found in people with schizophrenia.  
However, some of these requirements have not been met by the rl/rl because they 
have not yet been studied. For example, treatment responses in the rl/rl are still unknown. 
As Crawley (2000) made apparent, an animal model must respond appropriately to a 
treatment effectively used in humans with the disorder, but the animal also must not 
respond positively to treatments that do not improve symptoms in humans with the 
disorder. However, a search of the literature revealed no published studies of rl/rl mice 
being treated with any drug, much less an antipsychotic drug such as those used to treat 
schizophrenia.  It should be noted that +/rl but not rl/rl mice have been tested in various 
behavioral assays following the administration of various drugs, including 
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benzodiazepines (e.g., Costa, Davis, Pesold, Teuting, & Guidotti, 2002; Tremolizzo, 
Carboni, Ruzicka, Mitchell, et al., 2002; Carboni, Teuting, Tremolizzo, Sugaya, et al., 
2004). However, these experiments did not include rl/rl mice, which is the genotype 
proposed here to be a behavioral model of schizophrenia, and the drugs used in the 
experiments by Costa’s group were not drugs that have been approved to treat 
schizophrenia in humans. Accordingly, research into treatment effects on the rl/rl will 
begin by examining the effects of an antipsychotic drug, risperidone, used to treat 
schizophrenia in humans.    
 
Table 2 
The Reeler Mouse as a Model of Schizophrenia 
________________________________________________________________________ 
 
Criterion               Description and Sources  
Symptomatology          PPI, emotional, and cognitive deficits (Salinger et al., 2003) 
Treatment responsive           Unknown because unstudied 
Etiology                Reelin deficiencies (Curran & D’Arcangelo, 1998) 
Behavioral symptoms             PPI, emotional, and cognitive deficits (Salinger et al., 2003) 
Neuroanatomy               Abnormal lamination (D’Arcangelo & Curran, 1998) 
Neurochemical symptoms Reelin deficiencies (Curran & D’Arcangelo, 1998)     
Temporal progression            Unknown because unstudied 
Precipitating event            Unknown because unstudied 
________________________________________________________________________ 
 
 
Risperidone has been found to be more effective than haloperidol (a first-
generation, typical antipsychotic) at treating positive and negative symptoms of 
schizophrenia (Marder & Meibach, 1994) and cognitive deficits associated with the 
disease (Bilder, Goldman, Volavka, Czobor, et al., 2002). Because of its superiority over 
haloperidol, risperidone was predicted to be more likely to produce observable effects on 
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the rl/rl and so was the drug chosen to be used in this experiment.  
Previous studies investigating the effects of antipsychotics on animal models of 
schizophrenia have tended to focus on animals with disrupted PPI and have often limited 
or even avoided the use of measures of other schizophrenia-relevant behaviors. Whether 
deficits in PPI are induced or are naturally occurring in an animal, researchers use those 
animals to test new medications that could potentially treat schizophrenia patients (for a 
review, see Geyer et al., 2001), since disrupted PPI is a common feature in patients with 
schizophrenia that can be attenuated by antipsychotic medication (Kumari, Soni, & 
Sharma, 2002; Oranje et al., 2002; Duncan, Szilagyi, Schwartz, Kunzova, et al., 2003). 
Risperidone has been found to be effective at improving PPI both in mice naturally 
displaying deficient PPI (Ouagazzal, Jenck, & Moreau, 2001; Browman, Komater, 
Curzon, Rueter, et al., 2004) and in mice with experimentally-induced deficits in PPI (Le 
Pen & Moreau, 2002).   
In order to test further the hypothesis that rl/rl mice model schizophrenia, a 
pharmacological study was conducted in which risperidone was administered to the 
animals in order to determine if rl/rl mice’s cognitive, emotional, and sensorimotor 
gating deficits would improve in response to the drug. The specific prediction tested in 
this study was that the administration of risperidone to rl/rl mice would normalize their 
cognitive, emotional, and sensorimotor gating deficits, thereby causing rl/rl mice treated 
with risperidone to behave more like +/+ and +/rl mice not treated with the drug. If 
risperidone did significantly improve the deficits found in the rl/rl mouse, then this 
animal would gain further validation as an appropriate model for schizophrenia. 
   
9 
CHAPTER II 
 
METHOD 
 
 
Subjects 
 Fifty-four experimentally naïve mice (background strain, B6C3Fe a/a-, Jackson 
Laboratories, Bar Harbor, ME) bred in our animal colony served as subjects, divided as 
shown in Table 3. Crawley (1999) stated that there should be 10 animals of each 
genotype per condition for standardized experimental designs and appropriate statistical 
tests. Thus, 60 animals were needed for this experiment; however, due to difficulties in 
breeding and an unexpectedly high neonatal mortality rate in our colony, we were able to 
obtain only 54 animals for experimentation.  
 
Table 3 
Distribution of Subjects by Sex, Genotype, and Drug Condition 
_______________________________________________________________________                     
    
 +/+ +/rl rl/rl 
________________________________________________________________________ 
 
Vehicle        5 Males / 6 Females  3M / 4F             5M / 4F 
Risperidone                 5M / 5F 4M / 4F 5M / 4F 
________________________________________________________________________ 
 
 
Breeding difficulties also required three separate cohorts of mice. The first cohort 
contained 28 mice, which consisted of 14 +/+ (six males), four +/rl (all female), and 10 
rl/rl (seven males). The second cohort contained 18 mice, which consisted of six +/+ 
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(three males), six +/rl (four males), and six rl/rl (two males). The last cohort contained 
only eight mice – one male +/+, three male +/rl, two female +/rl, one male rl/rl, and one 
female rl/rl. All animals were at least 70 days of age when behavioral trials began. 
Animals were housed in cages of 2-4 same-sex littermates, and food and water were 
available ad libitum at all times, except during nose-poke testing, as described below. 
All behavioral testing occurred between 1100 and 1700h. Testing protocols were 
approved by the Institutional Animal Care and Use Committee at the University of North 
Carolina at Greensboro.  
Drug Treatment 
Each day, animals in the drug condition received 1.0 mg of risperidone per kg of 
body weight via oral gavage. This dose was chosen because it was consistently found to 
be effective in behavioral assays on rodents reported in the literature (Ouagazzal et al., 
2001; Le Pen & Moreau, 2002).  We also pilot tested 11 male animals (five rl/rl and six 
+/+) by giving them either risperidone or vehicle for three weeks and testing them in PPI 
at the end of each week. Results showed that there was a significant effect of the drug 
after the third test, which suggested that a three-week exposure to 1.0 mg/kg per day of 
risperidone by gavage should be sufficient to produce differential genotype responses to 
the drug, if those differences truly existed.  
Thus, three weeks prior to experimental testing for each cohort, all animals in the 
drug group began receiving risperidone, in water, via oral gavage at the rate of 1.0 mg/kg 
of body weight. One-milligram tablets of risperidone  (obtained through a generous 
donation from a local psychiatrist, Dr. Raouf Badawi) were dissolved in 2.0 mL of tap 
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water. The animals in the vehicle control group began receiving comparable oral gavage 
administrations of water.  
Drug/vehicle administration continued until the end of behavioral testing. Each 
day, animals received the drug or vehicle beginning at 1700h (+/- 30min) and all animals 
in the then currently-running cohort were dosed. Studies suggest that blood and brain 
levels remain within therapeutic limits for risperidone and its active metabolite, 9-
hydroxyrisperidone, for 24 hours in both rodents (Aravagiri & Marder, 2002) and humans 
(Möller, 2005; Megens, Awouters, Schotte, Meert, et al., 1994). Dosing in such a fashion 
also gave the animals an entire night to recover from any stress associated with gavage 
dosing before being tested.  
Materials and Procedures 
 Behavioral data were collected in five behavioral assays - open field, light-dark, 
PPI, nose-poke, and passive avoidance, in that order - which measure emotionality, 
sensorimotor gating, and cognitive functioning (Crawley, 2000). The order in which 
individual animals in a cohort were run through each test was determined by random 
assignment of cages.  
Tests of Emotionality  
Assessments of open field and light-dark performance used the TruScan apparatus 
and TruScan 2.01 software (Coulbourn Instruments, Allentown, PA). The TruScan arena 
is a clear acrylic enclosure, open on top, 26 cm square and 40 cm high. Two sensor 
beams arrays that detect animal movement are adjusted in height for each assay, and 
accessory equipment is added as needed to modify the TruScan arena for each individual 
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test. Two independent sets of TruScan apparatus permit the testing of two individual mice 
concurrently. 
Open field. The open field (OF) test occurred in the empty TruScan arena. The 
only accessory added was a plain brown floorplate or dropping pan. One sensor beam, at 
floor level, measured the animal’s movement in the X, Y plane, while a second beam, six 
centimeters above the floor, measured the animal’s rearing movements.  
The open field test is designed to measure the level of an animal’s anxiety and its 
level of exploratory behavior when it is exposed to a novel environment (Crawley, 2000). 
Each animal was placed for one hour into the TruScan arena as described above. 
Dependent variables for this test are time spent at rest, time spent on the perimeter 
(defined as the area no more than 3.25 cm away from the walls) of the chamber as 
opposed to time spent in the middle (any area that is not in the margin), rearing, 
stereotypic movements (grooming, head bobbing and/or extensions, and short body 
extensions that displace the center of the animal no more than 1.52 centimeters and then 
return the animal to its starting point within two seconds), and defecation.  
In this test, normal animals initially exhibit behaviors that are consistent with 
anxiety; for example, most produce boli and remain in perimeter areas while exploring 
the arena. Throughout the hour-long trial, animals with normal executive functioning 
habituate to the new environment and their activity levels decrease dramatically. 
However, rl/rl mice produce significantly fewer boli and spend more time exploring non-
perimeter areas than do +/+ or +/rl mice, and they also produce many stereotyped 
movements. They also remain active longer than do control mice (Salinger et al., 2003). 
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It was predicted that the administration of risperidone to the rl/rl would cause the animals 
to respond to the open field environment in a manner more consistent with the behavior 
found in +/+ and +/rl mice; in other words, they would, for example, produce more boli 
and remain in perimeter areas more often.  
Light-dark. The light-dark (LD) test also occurred in the TruScan arena, with the 
same arrangement of sensor beams as used in the open field and with the same floorplate. 
Additionally, however, a four-sided, dark acrylic insert (25.4 cm long x 13.34 cm wide x 
38.74 cm high) with a small opening (4.14 cm x 4.14 cm) facing the center of the arena 
was placed into the arena, thereby dividing the arena into lighted and darkened halves. 
The insert is opaque to visible light but transmits the near-infrared illumination used by 
the sensor beams.  
The light-dark test provides another measure of anxiety (Crawley, 2000) and 
occurred for each animal the day after the animal was in the open field. The animal was 
placed into the TruScan arena, modified as described above, into the lighted half and 
allowed to explore for five minutes. Dependent variables are the latency to enter the 
darkened half of the chamber for the first time and the total number of transitions 
between the lighted and darkened halves. Most rodents prefer to spend more time in the 
dark, although mice like to explore novel environments as well (Crawley, 2000), so after 
the initial entry into the darkened half of the chamber, mice should transition fairly 
frequently. Rl/rl mice display a longer latency to enter the dark half of the chamber 
compared to +/+ and +/rl mice and therefore have fewer transitions (Salinger, et al., 
2003), which may mean that they are less anxious about being in the open than are 
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control mice (because they spend more time in the light half the chamber). These findings 
are again consistent with the idea that the rl/rl mice are displaying a schizophrenia-like 
flattened affect. It was predicted that administration of risperidone would decrease the 
latency of the rl/rl to enter the darkened half and increase the number of transitions the 
rl/rl made (i.e., it would cause the rl/rl to behave more like +/+ and +/rl mice). 
Test of Sensorimotor Gating 
 Prepulse inhibition of the startle response (PPI) was measured in the San Diego 
Instruments SR-LAB chamber with SR-LAB software (San Diego Instruments, San 
Diego, CA). The chamber is sound-attenuated and houses a platform containing a force 
transducer to capture a mouse’s body movements and convert them into a signal sent to a 
computer, which then converts the signal of the mouse’s movement after the beginning of 
a trial into a startle response amplitude.  
Mice were placed into a holding container that was placed onto the platform, 
which in turn was situated directly beneath a speaker mounted into the top of the startle 
chamber such that the speaker was directly above the mouse. White noise and white noise 
pulses were produced over the speaker.  
The PPI test was approximately 20 minutes and consisted of a five-minute 
habituation period, during which the animal was allowed to habituate to the environment 
and to the background-level white noise (65 dB). There were also 50 trials of five 
different trial types, resulting in ten trials for each trial type. The trial types were as 
follows: 1) background noise only; 2) startling, 120-dB stimulus only (no prepulse); 3) 
startling stimulus preceded by a prepulse of 76 dB; 4) startling stimulus preceded by a 
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prepulse of 80 dB; and 5) startling stimulus preceded by a prepulse of 84 dB. Each 
animal experienced the same five trial types in the same order as every other mouse; 
however, the order of presentation for each trial type when the program was written was 
randomly determined. On trials on which they were used, prepulses were produced for 20 
milliseconds and there were 80 milliseconds from the offset of the prepulse to the onset 
of the startling stimulus, which was produced for 40 milliseconds. On startle-only trials, 
the startling stimulus was not preceded by a prepulse and was produced for 40 
milliseconds. On background only trials, no audible stimuli other than background-level 
white noise were produced. The interval between trials was randomly assigned, ranging 
between nine and 25 seconds.  
Normal animals are able to inhibit a startle response to the startling stimulus if the 
startle is preceded by a non-startling prepulse. Rl/rl mice, however, are significantly less 
able to reduce the amplitude of their startle response when the startle stimulus is preceded 
by a prepulse (Salinger et al., 2003); that is, rl/rl mice have a weak PPI. It was predicted 
that risperidone would increase the rl/rl mouse’s PPI to levels more consistent with +/rl 
and +/+ animals.  
Tests of Learning and Memory 
Nose-poke. Nose-poke (NP) testing occurred in the TruScan arena with several 
important changes to assess reference and working memory. An aluminum floorplate was 
inserted into the TruScan arena. This floorplate consists of 16 evenly spaced holes, and 
0.95 cm under the floorplate is a sub-floor with 16 wells, one directly beneath each hole. 
One sensor beam was placed at the level of the sub-floor, thus recording each time the 
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animal pokes its nose into the well, and one sensor beam was placed at the level of the 
aluminum floorplate, thus measuring each movement of the animal in the X, Y plane as 
well.  
Because this test used food rewards in order to measure reference and working 
memory, before assessment could begin each animal had its weight reduced to between ~ 
85% to ~ 90% of free-feeding body weight. Fragments (~0.006 g) of Nestle’s® chocolate 
mini-morsels were placed into four of the sixteen wells of the sub-floor; the same four 
were the only ones baited throughout testing. Animals were habituated to the task for two 
days to learn that the wells contain a food reward and to learn to eat the chocolate. 
(Different holes were used in the habituation task than those used during testing.) Testing 
occurred over a period of seven days following the two days of habituation. On the 
testing days, animals were allowed up to five minutes to recover all four morsels, and 
testing ended when the animal visited the fourth baited hole for the first time. Variables 
of interest for this task include reference and working memory ratios each day, and the 
number of errors and repeat entries made each day. Reference memory is defined as the 
total number of entries and re-entries into baited holes divided by the total number of 
entries into all holes; that is, this measure defines how well the animal has learned which 
holes contain rewards based on the animal’s preferential entries into those holes. Ratios 
for spatial working memory are determined by dividing the number of novel entries into 
baited holes by the total number of entries and re-entries into baited holes; in other words, 
this measure examines how well the animal remembers which of the baited holes it has 
already visited. Errors are defined as the total number of entries into unbaited holes from 
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the beginning of the task until the end of the task, and repeat entries are the total number 
of re-entries into any previously visited hole, whether baited or not. 
Rl/rl mice may have deficits in spatial working memory (Salinger et al., 2003). It 
was predicted that rl/rl mice on vehicle would make more errors during this task and 
have lower spatial working memory and reference memory ratios, and that the 
administration of risperidone would significantly decrease the number of errors and 
repeats that rl/rl make in this task, thereby improving their working and reference 
memory scores and causing them to appear more like +/+ and +/rl mice. 
Passive avoidance. Passive avoidance (PA) testing took place in the Coulbourn 
Instruments Habitest passive avoidance chamber with Graphic State 2.0 software 
(Coulbourn Instruments, Allentown, PA). The apparatus consists of a test chamber (7” x 
15” x 13”) that is divided into equally-sized halves. The right half of the chamber is 
covered with opaque black film, thus making this half of the chamber dark, while the left 
half has a house-light in the ceiling. A guillotine door separates the two halves. A 
dropping plate is placed beneath a shock-floor grid, which serves as the floor of the 
apparatus. The whole test chamber is placed inside a larger sound-attenuated chamber. 
The doors of the outer chamber have peep-holes that allow the experimenter to monitor 
the animals inside the apparatus.  
Similar to the light-dark assessment, this test relies on a rodent’s preference to be 
in the dark versus being in a well-lighted, open area. On the training day, an animal was 
placed into the left, lighted half of the test apparatus and allowed to explore for 60 
seconds, after which time the guillotine door between the halves opened. One second 
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after the mouse entered the darkened half, however, the door between the halves was 
closed and then the animal received a startling but non-painful 1.0 mA footshock that was 
two seconds in duration. After 30 seconds, the animal was returned to its home cage. The 
next day, the procedure was identical, except that the animal was not shocked upon 
entering the darkened chamber. The variable of interest in this task is the difference in 
latencies to enter the darkened chamber the first versus the second day. 
The protocol was set up such that an animal must have been entirely on the right 
side of the chamber (the darkened half) for one second before the door closed, and only 
after the door closed did the animal receive the shock. Although animals could explore 
around the door between halves and even partially enter the right side, thus breaking the 
sensor beam between halves, latencies to enter the right side of the chamber were defined 
as the entries that caused the door between halves to close. Animals that did not enter the 
right side of the chamber were assigned a latency of 300 seconds, because they were 
allowed up to five minutes to enter the right side before the test ended.  
This was the first time rl/rl mice had been tested in PA, and so their typical 
behaviors in this test were unknown. However, because previous research suggested that 
rl/rl mice may have deficits in response inhibition (Salinger et al., 2003), it was predicted 
that the rl/rl, compared to control mice, would be less able to suppress the tendency to 
enter the darkened chamber the second day, despite receipt of a shock upon doing so the 
previous day. Thus, it was predicted on the second day, after having received a footshock 
in the darkened chamber on the first day, that all mice would increase the latency of their 
entry into the darkened chamber. Moreover, it was predicted rl/rl mice would increase 
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their latency less than would the other genotypes, expressed as a percentage of the 
latency on day 1.  Finally, regarding risperidone effects, it was predicted that the 
administration of risperidone to rl/rl mice would cause the rl/rl to have longer latencies 
on the second day than they would if they had only received the vehicle solution, thereby 
causing them to behave more like +/+ and +/rl mice.  
However, after the first cohort of 28 animals had been tested in PA and it looked 
as though there were no genotype differences emerging, the methods were slightly altered 
for the next two cohorts (N=26) in such a way that experimental data could be collected 
in an uncontaminated fashion but would allow for a different method to be piloted. The 
first day of testing (the training day) was unchanged, but on the second day, animals were 
run through two trials instead of one. The first trial on the second day was another 
training trial, in which the animal received a shock upon entering the dark half of the 
chamber, as it had on the previous day’s trial. The second trial on the second day became 
the test trial and thus no shock was administered. The goal of this pilot testing was to 
determine if two training trials, instead of just one, would be sufficient to elicit genotype 
differences. Because the difference between the original method and the pilot method 
occurred only after the animal had already entered the dark half of the chamber on the 
first trial of the second day, the latency for which was the behavior of interest, that 
response was uncontaminated and was therefore commensurate with the latency data 
from the first 28 animals, and so the experimental data were uncorrupted. 
Startle response habituation (SRH). SRH data were obtained during the PPI test 
based on the maximum startle amplitude exhibited by animals on the 10 startle-only 
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trials. Rl/rl mice were found to show less habituation to the startle stimulus than +/rl and 
+/+ mice (Salinger et al., 2003), and it was predicted that the administration of 
risperidone would cause them to habituate to the startle stimuli similarly to +/+ mice. 
Statistical Analyses 
 A three-way analysis of variance (ANOVA) with genotype, treatment condition, 
and sex as between-subject factors was used to analyze the number of fecal boli produced 
in OF testing and the number of transitions between the light and dark halves and the 
initial latency to enter the dark in LD testing. Three-way ANOVAs with repeated 
measures, either across time, within a trial, or across multiple trials, with genotype, 
treatment condition, and sex as between-subject factors, were used to analyze all other 
measures. When a repeated-measures ANOVA revealed time as a significant factor in 
open field and nose-poke tests, polynomial extractions were used to account for its non-
random nature (Salinger et al., 2003). Main effects and interactions were analyzed with 
contrasts. Sex was included in analyses in order to avoid treating it as an error 
component; however, because too few of each sex were included in each condition, a 
reasonable interpretation of sex differences was not possible. Significance for all analyses 
was set at p< 0.05.  
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CHAPTER III 
RESULTS 
 
 
Analysis of Vehicle-Treated Animals 
The hypotheses in this experiment were based on observed differences between 
the rl/rl and the other two genotypes that were evident when none of the animals had 
received a drug manipulation (i.e., Salinger et al., 2003). Therefore, in order to ensure 
that unexpected genotype differences did not emerge as a result of stress related to the 
gavage procedure, or some other difference in experimentation that could confound the 
results and their interpretation, analyses were run separately for vehicle-treated animals 
only.  
Tests of Emotionality 
 Open field. A two-way analysis of variance with sex and genotype as between-
subjects variables for rest time during the first five minutes of open field exposure was 
non-significant overall, F(5, 21) = 1.8447, p= 0.1476, although the analysis for genotype 
was significant, F(2, 21) = 4.1137, p= 0.0311, with rl/rl mice spending less time at rest. 
 A two-way, repeated-measures analysis of variance with sex and genotype as 
between-subjects variables and with time as the within-subjects variable was used to 
analyze rest time over the 60-minute trial. The between-subjects analysis was significant 
overall, F(5, 21)= 11.8497, p< 0.0001. This was due to genotype: F(2, 21) = 28.9588, p< 
0.0001, in which the rl/rl spent significantly less time at rest than the +/rl and
   
+/+, F(1, 21) = 56.0877, p< 0.0001 (Figure 1). The other variables were not significant: 
sex, F(1, 21) = 2.2228, p= 0.1509, and sex x genotype, F(2, 21) = 0.3218, p= 0.7283. The 
within-subjects analysis did not reveal any significant results: time x sex, F(11, 11) = 
0.4381, p= 0.9066; time x genotype, F(22, 22) = 2.0277, p< 0.0523; and time x sex x 
genotype, F(22, 22) = 1.0462, p< 0.4583. 
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Figure 1. Rest Time in OF, Vehicle Animals Only. Time at rest in the open field for vehicle-treated animals 
only. Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. 
 
 
 The number of boli produced was analyzed with a two-way analysis of variance 
with sex and genotype as between-subjects variables. The ANOVA was significant 
overall, F(5, 21) = 3.1368, p= 0.0287. There was a significant main effect of genotype, 
F(2, 21) = 4.7863, p= 0.0194, but not for sex, F(1, 21) = 0.8308, p= 0.3724, nor was the 
interaction of sex and genotype significant, F(2, 21) = 2.7491, p= 0.0870. Contrasts 
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showed that the rl/rl produced significantly more boli in the open field than did the +/rl   
and +/+, F(1, 21) = 8.4342, p= 0.0085 (Figure 2).  
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Figure 2. Boli in OF, Vehicle Animals Only. Number of boli produced in the open field by vehicle-treated 
animals only. H= +/rl, R= rl/rl, and W= +/+. 
 
 
The percentage of time spent in the margins of the open field was analyzed with a 
two-way repeated-measures ANOVA with sex and genotype as between-subjects 
variables and with time as the within-subjects variable. The between-subjects analysis 
was significant overall, F(5, 21) = 3.8292, p= 0.0127. There was not a significant main 
effect of sex, F(1, 21) = 0.0908, p= 0.7661, nor was the interaction of sex and genotype 
significant, F(2, 21) = 0.3804, p= 0.6882. There was a significant main effect of 
genotype, F(2, 21) = 8.7288, p= 0.0017. A contrast showed that the rl/rl spent a 
significantly smaller percentage of time in the margins compared to +/rl and +/+, F(1, 21) 
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= 16.7069, p= 0.0005 (Figure 3). The within-subjects analysis revealed a significant time 
x sex interaction, F(11, 11) = 2.9956, p= 0.0411, in which females showed a more 
consistent increase over time in the percentage of time spent in the margins compared to 
males. There was not a significant time x genotype interaction, F(22, 22) = 1.8256, p= 
0.0830, nor was time x sex x genotype significant, F(22, 22) = 1.4282, p= 0.2049.  
 
Percentage of Time in Margins, Vehicle Animals Only
0
20
40
60
80
100
120
1 2 3 4 5 6 7 8 9 10 11 12
5-min bin
Pe
rc
en
ta
ge
 o
f T
im
e
H
R
W
 
Figure 3. Percentage of Time in Margins, Vehicle Animals Only. The percentage of time spent in the 
margins of the open field for vehicle-treated animals only. Triangles represent +/rl, squares represent rl/rl, 
and circles represent +/+. 
 
 
The number of stereotypic movements was also analyzed with a two-way repeated-
measures ANOVA. The between-subjects analysis was significant overall, F(5, 21) = 
6.7199, p= 0.0007. There was not a main effect of sex, F(1, 21) = 0.4149, p= 0.5264, nor 
was there a significant interaction of sex and genotype, F(2, 21) = 1.5216, p= 0.2415. 
There was a significant main effect of genotype, F(2, 21) = 15.0265, p< 0.0001, and a 
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contrast showed that this was due to the rl/rl, who made more stereotypic movements 
compared to +/rl and +/+ mice, F(1, 21) = 30.0471, p< 0.0001 (Figure 4).  
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Figure 4. Stereotypy Moves in OF, Vehicle Animals Only. The number of stereotypy moves made by 
vehicle-treated animals only. Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. 
 
 
The within-subjects analysis did not reveal a significant time x sex interaction,  
F(11, 11) = 1.5304, p= 0.2459, nor a significant time x sex x genotype interaction,  
F(22, 22) = 1.6383, p= 0.1274. There was a significant time x genotype interaction, F(22, 
22) = 2.1235, p= 0.0421. A contrast showed that the number of stereotypies produced by 
rl/rl remained fairly constant across time compared to +/+, who showed a steady decline 
in the number of stereotypic moves produced, F(11, 11) = 3.1101, p= 0.0364 (Figure 4). 
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Finally, the amount of rearing produced in the open field was also analyzed with a two-
way, repeated-measures ANOVA. The between-subjects analysis was not significant, 
F(5, 21) = 1.0352, p= 0.4230. The within-subjects analysis did not show a significant 
   
time x sex interaction, F(11, 11) = 0.8469, p= 0.6061, nor was there a significant time x 
sex x genotype interaction, F(22, 22) = 1.8843, p= 0.0725. There was a significant time x 
genotype interaction, F(22, 22) = 2.4557, p= 0.0202, in which both the +/rl, F(11, 11) = 
3.5945, p= 0.0222, and the rl/rl, F(11, 11) = 3.7813, p= 0.0185, differed from the +/+ 
(Figure 5). The +/+ showed a steady decline in the amount of rearing over time, but the 
+/rl showed a less obvious decline and reared more in the last half of the trial than did the 
+/+. The rl/rl displayed a more complex pattern of results, displaying very little rearing at 
the beginning of the trial and then showing more rearing as the trial progressed, but still 
reared less than did the +/+.  
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Figure 5. Rearing in OF, Vehicle Animals Only. Amount of rearing (number of vertical plane entries) in the 
open field for vehicle-treated animals only. Triangles represent +/rl, squares represent rl/rl, and circles 
represent +/+. 
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Light-dark. The latency of the initial entry to the dark half of the chamber was 
analyzed with a two-way analysis of variance, with sex and genotype as the between-
subjects factors. The ANOVA was not significant overall, F(5, 21) = 1.6148, p= 0.1997, 
although the analysis of genotype was significant, F(2, 21) = 3.7783, p= 0.0397, with rl/rl 
showing a much longer latency (Figure 6). 
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Figure 6. LD Latency, Vehicle Animals Only. The latency to enter the dark half of the chamber in the 
light/dark test for vehicle-treated animals only. H= +/rl, R= rl/rl, and W= +/+. 
 
 
 The number of transitions between halves was also analyzed with a two-way 
ANOVA. This analysis was also non-significant, F(5, 21) = 2.5389, p= 0.0601, although 
genotype was significant, F(2, 21) = 3.6130, p= 0.0448, with rl/rl mice showing fewer 
transitions (Figure 7).  
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Figure 7. LD Transitions, Vehicle-Treated Animals Only. The number of transitions between halves in the 
light-dark test for vehicle-treated animals only. H= +/rl, R= rl/rl, and W= +/+. 
 
Test of Sensorimotor Gating 
The amplitude of startle response on trials in which there was a prepulse was 
compared to the amplitude when only a startle stimulus occurred, for each prepulse 
intensity and each animal. Prepulse inhibition of startle (PPI) was the percent reduction of 
the startle response amplitude when both a prepulse and startle stimulus are presented 
relative the startle response amplitude when only a startle stimulus occurs. First, means 
were obtained for each of the five trial types (background only, startle only, and the three 
prepulse trial types - 76 dB, 80 dB, and 84 dB). The mean startle response for 
background-only trials was subtracted from the mean startle responses for each of the 
other trial types in order to correct for baseline movement. To obtain the measure of PPI 
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for each of the three prepulse intensities, the background-corrected means were used in 
the following formula for each animal: (mean startle on startle-only trials - mean startle 
on prepulse trials)/(mean startle on startle-only trials). The fraction that was obtained in 
this formula was then multiplied by 100 to obtain a percentage.  
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Figure 8. PPI, Vehicle Animals Only. Percent reduction of startle for vehicle-treated animals only. 
Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. 
 
 
The percent decrease in startle response on prepulse trials was analyzed with a 
two-way repeated-measures ANOVA with sex and genotype as between-subjects factors 
and with prepulse intensity as the within-subjects factor. The between-subjects analysis 
was not significant overall, F(5, 21) = 1.7351, p= 0.1704, although the analysis of 
genotype was significant, F(2, 21) = 3.5610, p= 0.0466, with rl/rl mice showing less PPI 
than the other two genotypes (Figure 8). The within-subjects analysis did not reveal any 
29 
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significant results: prepulse intensity x sex, F(2, 20) = 1.5551, p= 0.2356; prepulse 
intensity x genotype, F(4, 40) = 1.0180, p< 0.4097; and prepulse intensity x sex x 
genotype, F(4, 40) = 0.2363, p< 0.9162. 
Tests of Learning and Memory 
 Nose-poke. Reference memory was analyzed with a two-way repeated-measures 
analysis of variance, with sex and genotype as between-subjects variables and with time 
as the within-subjects variable. The between-subjects ANOVA was not significant, F(5, 
21) = 2.2994, p= 0.0816. The within-subjects analysis also did not reveal any significant 
results: time x sex, F(6, 16) = 2.1113, p= 0.1089; time x genotype, F(12, 32) = 0.6245, p= 
0.8056; and time x sex x genotype, F(12, 32) = 1.2221, p= 0.3111. 
 Working memory was analyzed as well, with a two-way, repeated-measures 
ANOVA. The between-subjects analysis was not significant, F(5, 21) = 2.6419, p= 
0.0528. The within-subjects analysis did not reveal any significant results: time x sex, 
F(6, 16) = 1.1072, p= 0.4006; time x genotype, F(12, 32) = 1.4730, p= 0.1857; and time x 
sex x genotype, F(12, 32) = 0.7765, p= 0.6695.  
The number of errors (defined above) made was analyzed with a two-way, 
repeated-measures analysis of variance. The between-subjects analysis was significant 
overall, F(5, 21) = 6.2260, p= 0.0011. There was not a significant main effect for 
genotype, F(2, 21) = 2.8728, p= 0.0789, but there was a main effect of sex, F(1, 21) = 
9.9652, p= 0.0048, and sex x genotype was also significant, F(2, 21) = 7.7789, p= 0.0030. 
A contrast showed that female +/rl mice made significantly more errors compared to 
female rl/rl and +/+ mice, F(1, 21) = 21.2625, p= 0.0002 (Figure 9). The within-subjects 
   
analysis did not reveal any significant results: time x sex, F(6, 16) = 1.4994, p= 0.2407; 
time x genotype, F(12, 32) = 1.1346, p< 0.3685; and time x sex x genotype, F(12, 32) = 
0.6176, p< 0.8114.  
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Figure 9. NP Errors, Female Vehicle Animals Only. Errors made in NP by female, vehicle-treated animals 
only. Triangles represent female +/rl, squares represent female rl/rl, and circles represent female +/+. 
 
Finally, the number of repeat entries, defined as the total numbers of re-entries to 
any previously visited hole on a given day, was analyzed with a two-way, repeated-
measures ANOVA. The between-subjects ANOVA was significant overall, F(5, 21) = 
3.4894, p= 0.0188. There was not a main effect either of sex, F(1, 21) = 2.7590, p= 
0.1116, or of genotype, F(2, 21) = 0.7918, p= 0.4661, but there was a significant 
interaction of sex and genotype, F(2, 21) = 6.9166, p= 0.0049. A contrast showed that the 
male rl/rl differed significantly from the male +/rl and +/+, F(1, 21) = 8.2234, p= 0.0092, 
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in that the male rl/rl made significantly more repeat entries than did the other two male 
genotypes (Figure 10). The within-subjects analysis did not reveal any significant results: 
time x sex, F(6, 16) = 2.6264, p= 0.0574; time x genotype, F(12, 32) = 1.2657, p< 
0.2852; and time x sex x genotype, F(12, 32) = 0.6501, p< 0.7838.  
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Figure 10. NP Repeats, Male Vehicle Animals Only. Repeat entries made in NP by male, vehicle-treated 
animals only. Triangles represent male +/rl, squares represent male rl/rl, and circles represent male +/+. 
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  Passive avoidance. Percent change in latencies for entry into the darkened half of 
the chamber were analyzed with a two-way, repeated-measures analysis of variance with 
sex and genotype as between-subjects variables and day as the within-subjects variable. 
The between-subjects analysis was non-significant, F(5, 21) = 1.1222, p= 0.3790, and the 
within-subjects analysis did not reveal any significant interactions: day x sex, F(1, 21) = 
0.5811, p= 0.4544; time x genotype, F(2, 21) = 1.1380, p= 0.3394; and time x sex x 
genotype, F(2, 21) = 0.1130, p= 0.8937. 
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Startle response habituation. Startle response habituation was analyzed by 
comparing the mean startle response amplitude for the first five startle-only trials to the 
mean startle response amplitude for the last five startle-only trials. The two means were 
compared with a two-way, repeated measures ANOVA with sex and genotype as the 
between-subjects variables and with block of trials as the within-subjects variable. The 
between-subjects analysis was not significant, F(5, 21) = 1.1319, p= 0.3744. The within-
subjects analysis also did not reveal any significant effects: block x sex, F(1, 21) = 
0.7499, p= 0.3963; block x genotype, F(2, 21) = 2.5492, p= 0.1021; and block x sex x 
genotype, F(2, 21) = 0.1554, p= 0.8571. 
Analysis of the Effects of Risperidone  
Tests of Emotionality 
 Open field. A three-way, between-subjects analysis of variance of rest time during 
the first five minutes of open field exposure with sex, genotype, and treatment condition 
as between-subjects variables was significant overall, F(11, 42) = 4.0387, p= 0.0005. 
There was a main effect of genotype, F(2, 42) = 18.7788, p< 0.0001 (Figure 11). A least-
squares means contrast showed that this was due to the rl/rl, who spent significantly less 
time at rest compared to the other two genotypes, F(1, 42) = 37.5384, p<0.0001. There 
were no other significant main effects or interactions: sex, F(1, 42) = 1.3169, p= 0.2576; 
sex x genotype, F(2, 42) = 0.3108, p= 0.7346; treatment condition, F(1, 42) = 0.0069, p= 
0.9340; sex x treatment condition, F(1, 42) = 0.2758, p= 0.6022; genotype x treatment 
condition, F(2,42) = 1.3334, p= 0.2745; and sex x genotype x treatment condition, F(2, 
42) = 0.5747, p= 0.5672. 
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Figure 11. First Five Minutes Rest Time in OF. Rest time in the first five minutes of open field exposure. 
H= +/rl, R= rl/rl, and W= +/+. 
 
 
As animals habituate to the open field over the hour-long trial, they tend to spend 
less time exploring and thus spend more time at rest. The between-subjects ANOVA for 
rest time during the 60-minute trial was significant overall, F(11, 42) = 10.7456, p< 
0.0001, and there was a significant main effect both for sex, F(1, 42) = 4.7957, p= 
0.0341, in which males spent more time at rest than females, and for genotype, F(2, 42) = 
56.3270, p< 0.0001 (Figure 12). Contrasts revealed that the genotype effect was due to 
the rl/rl, who spent less time at rest overall compared to +/+ and +/rl mice, F(1, 42) = 
108.6606, p< 0.0001. There were no other significant results revealed by the between-
subjects ANOVA: sex x genotype, F(2, 42) = 0.7666, p= 0.4710; treatment condition, 
F(1, 42) = 0.3646, p= 0.5492; sex x treatment condition, F(1, 42) = 0.1133, p= 0.7381; 
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genotype x treatment condition, F(2, 42) = 0.8769, p= 0.4235; and sex x genotype x 
treatment condition, F(2, 42) = 0.0544, p= 0.9471.  
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Figure 12. Rest Time in OF by Genotype. The mean amount of time spent at rest over the 60-minute trial. 
Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. 
  
 
The repeated-measures, within-subjects ANOVA for rest time revealed a 
significant time x genotype interaction, F(22, 64) = 1.8861, p< 0.0259. Time x sex x 
genotype was also significant, F(22, 64) = 2.2444, p< 0.0064. Contrasts revealed that 
male rl/rl spent significantly less time at rest than did male +/rl and +/+ mice, F(11, 32) = 
2.3450, p= 0.0298 (Figure 13). The other results were not significant: time x sex, F(11, 
32) = 1.2790, p= 0.2803; time x treatment condition, F(11, 32) = 0.5775, p= 0.8325; time 
x sex x treatment condition, F(11, 32) = 1.0850, p= 0.4032; time x genotype x treatment 
condition, F(22, 64) = 1.0660, p< 0.4052; and time x sex x genotype x treatment 
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condition, F(22, 64) = 0.4369, p< 0.9834. 
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Figure 13. Rest Time in OF, Male Vehicle Animals Only. Time at rest during open field for male animals. 
Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. 
 
Polynomial contrasts revealed a significant genotype x linear interaction, F(2, 42) 
= 7.8993, p= 0.0012, in which the +/rl showed a different pattern of increasing time at 
rest compared to both the rl/rl and the +/+, F(1, 42) = 6.4586, p= 0.0148, by starting off 
performing similarly to the +/+ but then leveling off in the last half of the trial compared 
to the +/+. There was also a significant genotype x cubic component, F(2, 42) = 3.2542, 
p= 0.0485, in which the rl/rl compared to the +/rl and +/+ steadily spent more time at rest 
as the first 45 minutes of the trial progressed before increasing time at rest markedly over 
the next five minutes and then leveling off for the last 10 minutes of the trial, F(1, 42) = 
5.5168, p= 0.0236 (Figure 12). 
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The number of fecal boli produced by each animal during its trial was counted in 
order to obtain an autonomic measure of anxiety-related arousal that is not dependent on 
normal locomotor coordination (Salinger et al., 2003). A three-way ANOVA with sex, 
genotype, and treatment condition as between-subjects factors revealed a significant main 
effect of genotype, F(2, 42) = 7.3297, p= 0.0019, which appeared to be part of the larger 
interaction of sex and genotype, F(2, 42) = 4.2197, p= 0.0214. A least-squares means 
contrast showed that the male +/rl produced significantly more boli than did the female 
+/rl, F(1, 42) = 4.6054, p= 0.0377. All other results were non-significant; sex, F(1, 42) = 
0.0623, p= 0.8042; treatment condition, F(1, 42) = 1.5852, p= 0.2150; sex x treatment 
condition, F(1, 42) = 0.9626, p= 0.3321; genotype x treatment condition, F(2, 42) = 
0.3982, p= 0.6740; and sex x genotype x treatment condition, F(2, 42) = 0.1340, p= 
0.8750.  
 The proportion of time spent in the marginal areas of the open field compared to 
central areas is also a measure of anxiety; high levels of anxiety are associated with a 
higher proportion of time spent in the marginal areas (Salinger et al., 2003). The three-
way between-subjects ANOVA was significant overall, F(11, 42) = 5.4106, p< 0.0001, 
and there was a significant main effect of genotype, F(2, 42) = 26.6808, p< 0.0001. 
Contrasts showed that this effect was also due to the rl/rl, who spent a significantly 
smaller proportion of time overall in the margins compared to +/rl and +/+ mice, F(1, 42) 
= 50.4557, p< 0.0001 (Figure 14). There were no other significant main effects or 
interactions: sex, F(1, 42) = 0.8601, p= 0.3590; sex x genotype, F(2, 42) = 0.7978, p= 
0.4570; treatment condition, F(1, 42) = 0.0229, p= 0.8804; sex x treatment condition, F(1, 
   
42) = 0.2068, p= 0.6516; genotype x treatment condition, F(2, 42) = 0.4233, p= 0.6576; 
and sex x genotype x treatment condition, F(2, 42) = 0.1614, p= 0.8515.  
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Figure 14. Percent Margin Time by Genotype. The mean percentage of time spent in the margins of the 
open field by genotype over the 60-minute trial. Triangles represent +/rl, squares represent rl/rl, and circles 
represent +/+. 
 
 
The repeated-measures, within-subjects ANOVA revealed no significant results, 
although time x genotype approached significance, F(22, 64) = 1.6934, p< 0.0533. The 
results for time x sex were F(11, 32) = 1.0348, p= 0.4405; time x sex x genotype, F(22, 
64) = 1.2270, p< 0.2585; time x treatment condition, F(11, 32) = 1.5451, p= 0.1639; time 
x sex x treatment condition, F(11, 32) = 1.1605, p= 0.3513; time x genotype x treatment 
condition, F(22, 64) = 0.7455, p= 0.7755; and time x sex x genotype x treatment 
condition, F(22, 64) = 1.6868, p< 0.0546. 
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 However, there was a main effect of time, F(11, 32) = 6.6934, p< 0.0001, and so 
polynomial extractions were used. These extractions revealed a significant genotype x 
linear interaction, F(2, 42) = 7.5599, p= 0.0016. Contrasts showed that rl/rl mice spent a 
significantly smaller proportion of time in the margins than did the other two genotypes, 
F(1, 42) = 13.6322, p= 0.0006 (Figure 14).   
The number of small, non-locomotor, repetitive movements (stereotypies) made 
by each animal during the hour-long session was also recorded. A between-subjects 
ANOVA was significant overall, F(11, 42) = 5.6439, p< 0.0001, and there was also a 
significant main effect of genotype, F(2, 42) = 25.4304, p< 0.0001. Contrasts showed that 
this main effect was due to the rl/rl, who made significantly more stereotypic movements 
when compared to the +/rl and +/+, F(1, 42) = 48.4438, p< 0.0001 (Figure 15). There 
were no other significant main effects or interactions: sex, F(1, 42) = 0.7314, p= 0.3973; 
sex x genotype, F(2, 42) = 1.9682, p= 0.1524; treatment condition, F(1, 42) = 3.4192, p= 
0.0715; sex x treatment condition, F(1, 42) = 0.0185, p= 0.8925; genotype x treatment 
condition, F(2, 42) = 1.7953, p= 0.1786; and sex x genotype x treatment condition, F(2, 
42) = 0.0196, p= 0.9806.  
A repeated-measures, within-subjects ANOVA with sex, genotype, and treatment 
condition as between-subjects factors and time as the within-subjects factor revealed a 
significant time x genotype interaction, F(22, 64) = 2.5717, p< 0.0018. Contrasts showed 
that rl/rl mice were significantly different from +/rl and +/+ mice, F(11, 32) = 2.1234, p= 
0.0479, in that they produced more of these movements than the other two genotypes. 
Also, +/rl mice were significantly different from +/+ mice, F(11, 32) = 3.0394, p= 
   
0.0069; while +/+ mice showed a steady decline in the number of such movements made 
over time, the number of these stereotypic movements made by the +/rl remained much 
more constant (Figure 15). 
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Figure 15. Stereotypy Moves in OF by Genotype. Mean number of repetitive, non-locomotor movements 
made by each genotype. Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. 
 
 
The analyses did not show any other significant results: time x sex, F(11, 32) = 0.7615, 
p= 0.6739; time x sex x genotype, F(22, 64) = 0.9566, p< 0.5273; time x treatment 
condition, F(11, 32) = 0.9170, p= 0.5362; time x sex x treatment condition, F(11, 32) = 
1.3936, p= 0.2234; time x genotype x treatment condition, F(22, 64) = 1.1086, p< 0.3622; 
and time x sex x genotype x treatment condition, F(22, 64) = 0.8347, p< 0.6732. 
 Polynomial extractions for stereotypic movements revealed a significant genotype 
x linear component, F(2, 42) = 14.7056, p< 0.0001. The polynomial extractions also 
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revealed a significant sex x genotype x linear component, F(2, 42) = 3.3324, p= 0.0454, 
in which the male and female rl/rl differed significantly from one another, F(1, 42) = 
5.0504, p= 0.0229; female rl/rl mice were fairly stable in the number of stereotypic 
movements they made over the trial, while male rl/rl mice showed a sharp decline in the 
last half of the trial compared to the first half, when they performed similarly to the 
females. There was also a significant sex x genotype x cubic component, F(2, 42) = 
3.4860, p= 0.0397, in which male and female +/rl mice differed significantly from one 
another, F(1, 42) = 4.3613, p= 0.0429; males and females showed a similar decreasing 
trend during the first two-thirds of the trial, and then males increased stereotypic 
movements relative to females. Additionally, there was a significant genotype x quadratic 
component, F(2, 42) = 4.7030, p= 0.0144, in which the +/rl significantly differed from 
both the rl/rl and the +/+, F(1, 42) = 8.6726, p= 0.0052. Finally, there was a significant 
sex x treatment condition x quadratic interaction, F(1, 42) = 5.7392, p= 0.0211, in which 
males and females in the vehicle condition differed from one another, F(1, 42) = 4.3099, 
p= 0.0440; males and females showed similar decreasing trends until the last 10 minutes 
of the trial, in which males continued to decrease but females increased (Figure 16). This 
difference was not found for the risperidone-treated animals (Figure 17). 
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Figure 16. Stereotypy Moves in OF by Gender, Vehicle Condition. Mean number of stereotypic movements 
made by animals in the vehicle condition during the open field test. Females are represented by triangles 
and males by squares. 
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Figure 17. Stereotypy Moves in OF by Gender, Risperidone Condition. Mean number of stereotypic 
movements made by animals in the risperidone condition during the open field test. Females are 
represented by triangles and males are represented by squares. 
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Rearing (i.e., vertical plane entries) during the trial was measured as well. A 
three-way, between-subjects ANOVA of rearing activity was not significant, F(11, 42) = 
1.0800, p= 0.3997. A repeated-measures, within-subjects ANOVA revealed a significant 
time x genotype interaction, F(22, 64) = 1.9809, p< 0.0180. Contrasts showed that the 
rl/rl differed significantly from the +/+ and +/rl by rearing more as the trial progressed 
instead of rearing less, as did the +/rl and +/+, F(11, 32) = 3.1456, p= 0.0055, while +/rl 
and +/+ did not significantly differ from one another, F(11, 32) = 1.0797, p= 0.4070 
(Figure 18). There were no other significant results for the within-subjects analysis: Time 
x sex, F(11, 32) = 0.6431, p= 0.7786; time x sex x genotype, F(22, 64) = 1.0902, p< 
0.3804; time x treatment condition, F(11, 32) = 0.8250, p= 0.6167; time x sex x treatment 
condition, F(11, 32) = 0.9404, p= 0.5164; time x genotype x treatment condition, F(22, 
64) = 0.8171, p< 0.6941; time x sex x genotype x treatment condition, F(22, 64) = 
0.5911, p< 0.9147.  
Polynomial extractions revealed a significant genotype x linear component for 
rearing, F(2, 42) = 16.1311, p< 0.0001. A contrast showed that rl/rl mice significantly 
differed from both +/rl and +/+ mice, F(1, 42) = 24.2057, p< 0.0001 . Rl/rl mice had 
more erratic behavior than the other two genotypes, but had fewer rearing incidents 
overall until the last third of the trial, when the +/+ decreased to less than the rl/rl. There 
was also a significant genotype x cubic component, F(2, 42) = 3.3629, p= 0.0442. A 
contrast showed that +/+ differed significantly from +/rl and rl/rl, F(1, 42) = 6.6524, p= 
0.0135. Unlike +/rl and rl/rl mice, who remained somewhat stable across time in the 
   
number of vertical entries made (although, again, rl/rl mice displayed a more complex 
pattern), +/+ mice showed a significant decreasing trend over the duration of the trial 
(Figure 18). 
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Figure 18. Rearing in OF by Genotype. Mean number of vertical plane entries (i.e., rearing) in the open 
field by genotype. Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. 
 
 
 Light-dark. The latency of each animal to make its initial crossing into the 
darkened half of the chamber was measured. A three-way ANOVA with sex, genotype, 
and treatment condition as between-subjects factors was significant overall, F(11, 42) = 
2.3977, p< 0.0206. The ANOVA also revealed a main effect of genotype, F(2, 42) = 
12.0644, p< 0.0001 (Figure 19). A least-squares means contrast revealed that this 
difference was due to the rl/rl, F(1, 42) = 23.0149, p< 0.0001, who showed a much 
longer latency to enter the dark than both the +/+ and +/rl. There were no other 
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significant main effects or interactions: sex, F(1, 42) = 0.0132, p= 0.8606; sex x 
genotype, F(2, 42) = 0.3004, p= 0.7421; treatment condition, F(1, 42) = 0.0155, p= 
0.9015; sex x treatment condition, F(1, 42) = 0.0736, p= 0.7875; genotype x treatment 
condition, F(2, 42) = 0.1910, p= 0.8268; and sex x genotype x treatment condition, F(2, 
42) = 0.6108, p= 0.5477. 
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Figure 19. Latency of First Dark Entry by Genotype. Mean latency to first entry to darkened half of light-
dark chamber by genotype. H=+/rl, R=rl/rl, and W=+/+. 
 
 
 A three-way ANOVA of the total number of transitions between the light and 
dark halves with sex, genotype, and treatment condition as between-subjects factors was 
also significant, F(11, 42) = 2.6796, p= 0.0106. There was again a main effect of 
genotype, F(2, 42) = 10.1286, p= 0.0003 (Figure 20). Least-squares means contrasts also 
revealed that this was due to the rl/rl, F(1, 42) = 20.2284, p< 0.0001, with rl/rl mice 
passing between the halves significantly less than the other two genotypes. There were no 
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other significant main effects or interactions: sex, F(1, 42) = 1.1964, p= 0.2803; sex x 
genotype, F(2, 42) = 1.3327, p= 0.2747; treatment condition, F(1, 42) = 0.2691, p= 
0.6066; sex x treatment condition, F(1, 42) = 0.0047, p= 0.9455; genotype x treatment 
condition, F(2, 42) = 1.3064, p= 0.2816; and sex x genotype x treatment condition, F(2, 
42) = 1.5325, p= 0.2278. 
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Figure 20. Transitions in LD by Genotype. Mean number of transitions between light and dark halves in 
light-dark test by genotype. H=+/rl, R=rl/rl, and W=+/+. 
 
 
Test of Sensorimotor Gating 
A repeated-measures, within-subjects ANOVA for percent reduction in startle 
response with sex, genotype, and treatment condition as between-subjects factors and 
prepulse intensity as the within-subjects factor, revealed a significant main effect of 
prepulse intensity, F(2, 41) = 18.1440, p< 0.0001, in which animals showed greater PPI 
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as the intensity of the prepulse increased. There was also a significant interaction of 
prepulse intensity and genotype, F(4, 82) = 5.6546, p< 0.0005. Contrasts showed that this 
result was due to the rl/rl, who failed to increase prepulse inhibition as prepulse intensity 
increased, compared to the +/+ and +/rl, F(2, 41) = 12.6155, p< 0.0001 (Figure 21).  
There were no other significant main effects or interactions; prepulse intensity x 
sex, F(2, 41) = 1.2042, p= 0.3103; prepulse intensity x sex x genotype, F(4, 82) = 0.5766, 
p< 0.6804; prepulse intensity x treatment condition, F(2, 41) = 0.1921, p= 0.8259; 
prepulse intensity x sex x treatment condition, F(2, 41) = 1.2783, p= 0.2894; prepulse 
intensity x genotype x treatment condition, F(4, 82) = 1.0659, p< 0.3787; and prepulse 
intensity x sex x genotype x treatment condition, F(4, 82) = 1.1366, p< 0.3451. 
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Figure 21. Percent Reduction in Startle. The mean percent reduction in startle response by genotype. 
Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. 
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Tests of Learning and Memory 
 Nose-poke. Reference memory ratios were determined each day during nose-poke 
testing, using the formula described above in the methods section. A between-subjects 
ANOVA was not significant, F(11, 42) = 1.2337, p= 0.2959. A repeated-measures, 
within-subjects ANOVA for reference memory with sex, genotype, and treatment 
condition as between-subjects factors and time as a within-subjects factor revealed no 
significant main effects or interactions; time x sex, F(6, 37) = 0.6798, p= 0.6668; time x 
genotype, F(12, 74) = 1.1111, p< 0.3644; time x sex x genotype, F(12, 74) = 1.1259, p< 
0.3530; time x treatment condition, F(6, 37) = 2.2352, p= 0.0612; time x sex x treatment 
condition, F(6, 37) = 2.2185, p= 0.0629; time x genotype x treatment condition, F(12, 74) 
= 0.5683, p< 0.8606; and time x sex x genotype x treatment condition, F(12, 74) = 
1.0108, p< 0.4480.  
 There was a significant main effect of time, F(11, 42) = 3.9002, p= 0.0006, and 
polynomial extractions revealed a significant treatment condition x quadratic interaction, 
F(1, 42) = 8.8497, p= 0.0048. Vehicle-treated animals had higher reference memory at 
the beginning of testing than did risperidone-treated animals, but then these ratios 
decreased for vehicle-treated animals while increasing for risperidone-treated animals, 
with risperidone-treated animals averaging slightly higher ratios until the end of testing, 
when both groups performed the same (Figure 22). 
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Figure 22. Reference Memory Ratios by Treatment Condition. Mean reference memory ratios in nose-poke 
testing over seven days by treatment condition. Closed triangles represent risperidone-treated mice and 
open squares represent vehicle-treated animals. 
 
 
Working memory ratios were also determined each day for each animal, using the 
formula described above in the methods section. A between-subjects ANOVA was 
significant overall, F(11, 42) = 2.7799, p= 0.0083. There was a significant main effect of 
genotype, F(2, 42) = 7.8605, p= 0.0013 as well as a significant interaction of sex and 
genotype, F(2, 42) = 3.4258, p= 0.0419. Contrasts showed that male and female rl/rl 
mice were significantly different from one another, F(1, 42) = 4.5312, p= 0.0392. Across 
the seven-day testing period, there were times when there were not any differences in 
working memory scores for male and female rl/rl, but overall the male rl/rl had lower 
working memory ratios than did the female rl/rl (Figure 23). There were not any other 
significant main effects or interactions: sex, F(1, 42) = 1.2124, p= 0.2771; treatment 
condition, F(1, 42) = 0.0893, p= 0.7665; sex x treatment condition, F(1, 42) = 0.2798, p= 
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0.5996; genotype x treatment condition, F(2, 42) = 1.1517, p= 0.3259; and sex x 
genotype x treatment condition, F(2, 42) = 1.5125, p= 0.2321.  
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Figure 23. Working Memory Ratios for Reelers. Working memory ratios for male and female rl/rl. Closed 
squares represent female rl/rl and open squares represent male rl/rl. 
 
 
A repeated-measures, within-subjects ANOVA revealed no significant effect of 
time x sex, F(6, 37) = 1.5223, p= 0.1980, or of time x genotype, F(12, 74) = 1.5034, p< 
0.1422. There was a significant time x sex x genotype interaction, F(12, 74) = 2.0664, p< 
0.0297. A contrast revealed that male +/rl mice were significantly different from female 
+/rl mice, F(6, 37) = 2.6964, p= 0.0284, in that the female +/rl had lower working 
memory ratios than the male +/rl on days 2 and 4 but then had a higher working memory 
ratio on day 6 (Figure 24). There were no other significant effects; for time x treatment 
condition, F(6, 37) = 0.5514, p= 0.7656; time x sex x treatment condition, F(6, 37) = 
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0.6839, p= 0.6636; time x genotype x treatment condition, F(12, 74) = 0.7479, p<0.7004; 
time x sex x genotype x treatment condition, F(12, 74) = 0.3347, p<0.9802.  
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Figure 24. Working Memory Ratios for Hybrids. Working memory ratios for male and female +/rl. Closed 
triangles represent female +/rl and open triangles represent male +/rl. 
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The number of errors, defined as the total number of visits to never-baited holes 
during each trial, was also analyzed. A between-subjects ANOVA was significant 
overall, F(11, 42) = 2.1863, p= 0.0341, with a significant main effect of genotype, F(2, 
42) = 3.4380, p= 0.0414, and a significant interaction of genotype and treatment 
condition, F(2, 42) = 3.2690, p= 0.0479. Contrasts showed that the rl/rl on risperidone 
made more errors for the first four days than all other genotype and treatment condition 
groups, F(1, 42) = 7.1557, p= 0.0106 (Figure 25). There were no other main effects or 
interactions in the between-subjects analysis: sex, F(1, 42) = 0.6584, p= 0.4217; sex x 
genotype, F(2, 42) = 1.0838, p= 0.3476; treatment condition, F(1, 42) = 0.0000, p= 
   
0.9997; sex x treatment condition, F(1, 42) = 3.9393, p= 0.0537; and sex x genotype x 
treatment condition, F(2, 42) = 2.1744, p= 0.1263.  
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Figure 25. Nose Poke Task Errors. The number of errors made. Triangles represent +/rl, squares represent 
rl/rl, and circles represent +/+. Closed figures represent risperidone-treated animals and open figures 
represent vehicle treated animals. 
 
A repeated-measures, within-subjects ANOVA for task errors did not reveal any 
significant results; time x sex, F(6, 37) = 2.3235, p= 0.0528; time x genotype, F(12, 74) = 
1.7020, p< 0.0835; time x sex x genotype, F(12, 74) = 1.0695, p< 0.3979; time x  
treatment condition, F(6, 37) = 0.6555, p= 0.6856; time x sex x treatment condition, F(6, 
37) = 0.7682, p= 0.5997; time x genotype x treatment condition, F(12, 74) = 1.0940, p< 
0.3779; and time x sex x genotype x treatment condition, F(12, 74) = 0.5388, p< 0.8823. 
The number of times an animal went back to any previously visited hole, 
regardless of its status as a baited or non-baited hole, (“repeats”) was measured and 
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analyzed. A between-subjects ANOVA was significant overall, F(11, 42) = 3.4522, p= 
0.0017. There was a main effect of genotype, F(2, 42) = 8.2638, p= 0.0009, and a 
significant genotype x treatment condition interaction, F(2, 42) = 3.8387, p= 0.0294, 
which were part of the larger sex x genotype x treatment condition interaction, F(2, 42) = 
3.6364, p= 0.0350 (interpreted below). There were no other significant main effects or 
interactions revealed by the between-subjects analysis: sex, F(1, 42) = 0.0321, p= 0.8587; 
sex x genotype, F(2, 42) = 1.7950, p= 0.1786; treatment condition, F(1, 42) = 0.2075, p= 
0.6511; and sex x treatment condition, F(1, 42) = 3.3875, p= 0.0728.  
In order to examine the three-way interaction above, a separate ANOVA was run 
for males and females with genotype and treatment as between-subjects variables. The 
ANOVA for males was not significant, F(5, 21) = 2.5274, p= 0.0610, but was significant 
for females, F(5, 21) = 7.9562, p= 0.0002. Genotype x treatment condition was also 
significant for females, F(2, 21) = 13.6553, p= 0.0002. A contrast showed that the female 
rl/rl on risperidone was significantly different from the female rl/rl treated with vehicle 
and from all female +/rl mice, F(1, 21) = 9.9206, p= 0.0048 (Figure 26). It is also obvious 
from plotting female rl/rl and female +/rl data separately that risperidone had opposite 
effects on these two genotypes; risperidone worsened female rl/rl performance (Figure 
27) but improved performance for female +/rl (Figure 28).  
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Figure 26. NP Repeats for Females. Mean numbers of repeats each day in the nose-poke test for female 
rl/rl and +/rl. Triangles represent +/rl and squares represent rl/rl. Closed figures represent animals treated 
with risperidone and open figures represent animals given vehicle. 
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Figure 27. NP Repeats for Female Reelers. Mean number of repeats made each day by female rl/rl. Open 
squares represent female rl/rl given vehicle and closed squares represent female rl/rl given vehicle. 
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Figure 28. NP Repeats for Female Hybrids. Mean number of repeats made by female +/rl in nose poke each 
day. Closed triangles represent risperidone-treated +/rl and open triangles represent vehicle-treated +/rl. 
 
 
A repeated-measures, within-subjects ANOVA for repeat entries revealed a 
significant time x sex interaction, F(6, 37) = 4.3770, p= 0.0020, in which males compared 
to females made fewer repeats on day 2 but more on day 6. There were no other 
significant results. For time x genotype, F(12, 74) = 1.8610, p< 0.0536; for time x sex x 
genotype, F(12, 74) = 1.6899, p<0.0864; for time x treatment condition, F(6, 37) = 
1.0778, p= 0.3934;  time x sex x treatment condition, F(6, 37) = 0.7020, p= 0.6498; time 
x genotype x treatment condition, F(12, 74) = 1.3569, p< 0.2063; and time x sex x 
genotype x treatment condition, F(12, 74) = 0.6114, p< 0.8260. 
Because time was a significant factor for this analysis, however, F(6, 37) = 
10.1061, p< 0.0001, polynomial extractions were run. There was a significant sex x linear 
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component, F(1, 42) = 7.4300, p= 0.0093 (similar to that reported above), and a 
significant genotype x treatment condition x linear component was also revealed, F(2, 42) 
= 4.2231, p= 0.0213. Rl/rl mice on risperidone were found to have made significantly 
more repeat entries compared to all other genotype x treatment condition groups during 
the first four days of testing before dropping to within the range of the other groups for 
the remaining days of the test (Figure 29), F(1, 42) = 6.7581, p= 0.0128. The significant 
genotype x treatment condition x cubic component verified these results, F(2, 42) = 
4.4128; rl/rl mice on risperidone compared to all other groups, F(1, 42) = 0.0159.  
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Figure 29. Nose Poke Repeats. Mean number of visits to previously visited holes in nose poke testing each 
day. Triangles represent +/rl, squares represent rl/rl, and circles represent +/+. Closed shapes represent 
risperidone-treated animals and open shapes represent vehicle-treated animals. 
 
 
Passive avoidance. Latencies to enter the dark side after the opening of the door 
dividing it from the lighted start chamber were analyzed with a three-way repeated-
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measures ANOVA with sex, genotype, and treatment condition as between-subjects 
variables and with day as the within-subjects variable. The between-subjects analysis was 
not significant, F(11, 42) = 1.3205, p= 0.2473. The within-subjects analysis returned a 
significant main effect of day, F(1, 42) = 69.7560, p< 0.0001, in which all animals 
significantly increased their latency to enter the right side on day 2 compared to day 1 
(Figure 30).  
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Figure 30. Latencies for PA by Genotype. Mean latencies in PA for days 1 and 2. H= +/rl, R= rl/rl, and 
W= +/+. 
 
 
There were no other significant interactions: day x sex, F(1, 42) = 0.6229, p= 
0.4344; day x genotype, F(2, 42) = 1.0025, p= 0.3756; day x sex x genotype, F(2, 42) = 
0.7463, p= 0.4803; day x treatment condition, F(1, 42) = 0.0025, p= 0.9600; day x sex x 
treatment condition, F(1, 42) = 0.1023, p= 0.7506; day x genotype x treatment condition, 
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F(2, 42) = 0.3249, p= 0.7244; and day x sex x genotype x treatment condition, F(2, 42) = 
0.9148, p= 0.4084. The percent change in latency was also figured for each animal using 
the following formula: (Latency day 2 - Latency day 1)/Latency day 1. The percent 
change in latency was analyzed with a three-way ANOVA, and it was non-significant 
overall, F(11, 42) = 0.4805, p= 0.9049. 
Startle response habituation. Startle response habituation was also measured, 
using the maximum startle amplitude on each of the 10 startle-only trials in the PPI test. 
The mean startle amplitude was obtained for startle trials one through five and for startle 
trials six through 10, and the two blocks of trials were compared to determine if the 
animals were habituating to the startle stimulus. The two means were analyzed with a 
repeated-measures ANOVA with sex, genotype, and treatment condition as between-
subject variables and with block of trials as a within-subjects variable.  
The between-subjects ANOVA was not significant, F(11, 42) = 0.8682, p= 
0.5768. The repeated-measures, within-subjects ANOVA also did not return any 
significant results: block x sex, F(1, 42) = 0.1176, p= 0.7333; block x genotype, F(2, 42) 
= 0.2099, p= 0.8115; block x sex x genotype, F(2, 42) = 0.0393, p= 0.9615; block x 
treatment condition, F(1, 42) = 0.1407, p= 0.7095; block x sex x treatment condition, F(1, 
42) = 0.5323, p= 0.4697; block x genotype x treatment condition, F(2, 42) = 2.6145, p= 
0.0851; and block x sex x genotype x treatment condition, F(2, 42) = 0.3713, p= 0.6921. 
Piloting Alternative Passive Avoidance Methods 
There were 26 animals that underwent the modified PA testing. Latency to the 
right side for each trial was analyzed with a three-way, repeated-measures ANOVA with 
   
sex, genotype, and treatment condition as the between-subjects variable and with day as 
the within-subjects variable.  
The between-subjects analysis was not significant, F(11, 14) = 0.4740, p= 0.8905, 
nor did the within-subjects analysis reveal any significant results: time x sex, F(2, 13) = 
0.3356, p= 0.7209; time x genotype, F(4, 26) = 1.7814, p< 0.1629; time x sex x genotype, 
F(4, 26) = 1.6717, p< 0.1867; time x treatment condition, F(2, 13) = 0.3974, p= 0.6799; 
time x sex x treatment condition, F(2, 13) = 1.3403, p= 0.2956; time x genotype x 
treatment condition, F(4, 26) = 0.2057, p< 0.9329; and time x sex x genotype x treatment 
condition, F(4, 26) = 0.5942, p< 0.6700. However, it appears that significant genotype 
differences may have been revealed with a larger sample size (Figure 31). 
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Figure 31. Latencies for 3-Trial PA Pilot. Mean latencies for three trials of passive avoidance by genotype. 
H= +/rl, R= rl/rl, and W= +/+. 
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CHAPTER IV 
DISCUSSION 
     
The purpose of this research was to test the hypothesis that the rl/rl mutant mouse 
is an appropriate animal model of schizophrenia, based on its deficits in sensorimotor 
gating, cognitive functioning, and emotionality (Salinger et al., 2003). It was predicted 
that if the rl/rl were an appropriate model of schizophrenia, then the atypical 
antipsychotic, risperidone, should reduce those deficits, because the drug has been shown 
to be effective in treating those symptoms in humans with schizophrenia (Kumari et al., 
2002; Oranje et al., 2002; Duncan et al., 2003; Bilder et al., 2002; Marder & Meibach, 
1994). This prediction was tested by administering the drug to the rl/rl and to two other 
genotypes, the +/+  (control) and the +/rl, with another group of these animals receiving 
the vehicle, tap water, and evaluating the performance of these groups on assays of 
cognitive functioning, emotionality, and sensorimotor gating.  
The hypotheses tested in this experiment were based on the assumption that the 
animals receiving vehicle instead of the drug would show genotype differences consistent 
with those differences found in the previous research by Salinger et al (2003). It is 
possible, however, that the daily gavage procedures used to administer vehicle and 
risperidone doses, or some other unintended difference in experimental conditions, might 
have made data from the current experiment incommensurate with those from Salinger et 
al (2003).  If those expected genotype differences were not found in this research for 
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animals in the vehicle condition, then these results could not be interpreted under the 
hypothesis that reelers are models of schizophrenia, because the risperidone would have 
been acting on animals displaying a modified phenotype. Therefore, genotype differences 
among animals in the vehicle condition had to be compared to previous research before 
interpretation of any possible risperidone effects could begin.
Moreover, there was one test (passive avoidance) used in the present experiment 
that was not used in Salinger et al. (2003), and two tests that used somewhat different 
methods (nose-poke) or parameters (open field). Because it was unknown how the 
different genotypes would typically respond on the PA test and under the current NP 
methods, the vehicle analysis was also important in determining whether or not these 
methods were adequate to test the hypotheses. If predicted genotype differences did not 
emerge in the vehicle analysis for these tests, then the tests would not be useful for 
confirming or denying the prediction that risperidone would improve deficits in the rl/rl. 
Analysis of Vehicle-Treated Animals  
Main effects of genotype from the current vehicle-only analysis are summarized in Table 
4, as well as the genotype results reported in Salinger et al. (2003). As can be seen, in 
most respects the gavage procedures did not interfere with the replication of findings 
from the three tests for which the current methods were the same as those used in the 
earlier study, suggesting that the methods employed for these tests are adequate for 
testing the current hypothesis that performance deficits in rl/rl mice should be diminished 
by risperidone treatment. The present vehicle analysis also confirms the observations by 
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Salinger et al. (2003), Groves et al. (2003), and Podhorna and Didriksen (2004) that the 
+/rl mice show no systematic behavioral differences from the +/+ mice. 
 
Table 4 
Hybrids and Reelers Compared to Wildtypes in Salinger et al., 2003, and in the Current 
Study (Vehicle Animals Only) 
________________________________________________________________________ 
 
           +/rl         rl/rl 
Test Measure           2003   Current           2003   Current 
OF 5-min rest time ↔              ↔         ↓  ↓* 
 60-min rest time ↔ ↔  ↓ ↓ 
 Boli ↔              ↔  ↓  ↑ 
 Margin Time ↔ ↔  ↓  ↓ 
 Stereotypy Moves ↔ ↔   ↑  ↑ 
 Rearing ↔  ↑  ↓  ↓  
LD Latency to Dark ↔ ↔  ↑  ↑* 
 Transitions  ↔              ↔  ↓  ↓* 
NP Reference Memory ↔ ↔  ↓ ↔ 
 Working Memory ↔ ↔  ↓ ↔ 
 Errors† NA ↔                          NA ↔ 
 Repeats† NA ↔                          NA ↔ 
PPI % Startle Reduction ↔ ↔  ↓  ↓ 
 Startle habituation ↔ ↔  ↓ ↔ 
PA Change in latency NA ↔                          NA ↔ 
________________________________________________________________________ 
Note: Horizontal arrows (↔) indicate values that are not significantly different from +/+ animals. Up 
arrows (↑) indicate values that are significantly greater than the values for +/+s. Down arrows (↓) indicate 
values that are significantly less than the values for +/+s. Significance was set at p < 0.05. NA indicates that 
either the measure was not reported or was not analyzed in the 2003 study. 
*The results for genotype were significant, but the overall ANOVA was not. 
†There was no main effect of genotype in the current study, although there was a sex x genotype 
interaction. 
 
 
 The open field test used in the current experiment was only slightly modified 
from Salinger et al’s previous (2003) research. In this study, the upper sensor beam, used 
to detect and measure rearing, was lowered by one centimeter to account for rl/rl mice’s 
ataxia and smaller body size, because visual observations of rl/rl mice in the open field 
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suggested that their body height when rearing was not adequate to break the sensor beam 
when it was positioned at seven centimeters above the ground. Though rl/rl mice showed 
significantly less rearing compared to +/+ mice both in the present study and in Salinger 
et al. (2003), visually comparing the rearing curves reported in Salinger et al. (2003) to 
the present figures for rearing suggests that the lower placement of the upper sensor beam 
in the current study did detect more rearing among rl/rl mice than was found in the earlier 
study, especially in the latter portion of the 60-minute trial. Conversely, although +/rl 
mice reared more than +/+ mice in the present study, comparing the two curves for 
rearing from Salinger et al. (2003) and the present study suggest that this difference was 
due to noise in the present study, because the two curves are very similar between 
studies. 
The nose-poke task was simplified in the current experiment compared to that 
used previously. In the 2003 study, spatial working memory was initially assessed with 
all 16 holes baited, and mice were tested in the 4-hole task only after they had already 
learned and been tested in the 16-hole task. In those experiments, when transferred from 
the 16-hole to the 4-hole version of the task, rl/rl mice initially showed inferior reference 
memory ratios compared to +/rl and +/+ mice, but after four days on the 4-hole version of 
the task, there were no genotype differences found for reference memory. The 4-hole 
version of the nose-poke task was used here because it was believed that genotype 
differences would still be found but would require fewer days of testing and fewer 
materials. However, for animals in the vehicle condition of the present research, not only 
were there no genotype differences in reference memory, but there were also no genotype 
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differences found in any of the other nose-poke measures. 
The discrepancy between the 2003 results for the nose-poke task, in which rl/rl 
mice showed deficits compared to other mice, and the current results, in which they did 
not, may be due to the fact that animals had to “unlearn” a harder, 16-hole nose-poke task 
before learning the simpler 4-hole version in the 2003 study, whereas animals in the 
current study did not have to do so. Thus, the more complex sequence used in the 2003 
task may have revealed genotype differences that are not seen in simpler tasks.  In any 
case, the current nose-poke procedures failed to distinguish between the genotypes in the 
vehicle condition and hence the current nose-poke results render uninterpretable the 
results of nose-poke experiments during risperidone treatment. 
Passive avoidance was used in the current study but not in Salinger et al. (2003). 
Because this was the first experiment to our knowledge to test rl/rl mice in passive 
avoidance, it was unknown whether they would behave differently from other mice. It 
was predicted, based on Salinger et al.’s (2003) previous research in which rl/rl mice 
displayed behaviors that could be interpreted as stemming from deficient response 
inhibition, that rl/rl mice would perform more poorly on passive avoidance (i.e., show a 
smaller difference between days 1 and 2 in latency to enter the right half of the chamber) 
than the other genotypes. However, the analyses of PA data under vehicle treatment did 
not show any genotype differences in passive avoidance.  
It is possible that vehicle-treated rl/rl mice do not display deficiencies in response 
inhibition compared to vehicle-treated +/+ mice after a single training session because 
more PA training was required than was provided in these experiments. The pilot data 
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from experiments in which PA training and testing extended to three trials suggest that 
genotype differences may emerge with the addition of a second training session.   
A review of the literature showed that, although the set-up of the test chamber 
may differ from experiment to experiment (e.g., a step-down versus a step-through test), 
and although the duration and intensity of the footshock may vary, the method of PA 
used here is a method commonly used by other researchers (i.e., having one training trial 
separated by 24 hours from the test trial) (Lukawski, Nieradko, & Sielklucka-Dziuba, 
2005; Taniguchi, Doe, Matsuyama, Kitamura, et al., 2005; Rasmussen, Fink-Jensen, 
Sauerberg, Swedberg, et al., 2001; Picciotto, Zoli, Léna, Bessis, et al., 1995; Ciamei, 
Aversano, Cestari, & Castellano, 2001). However, there are also researchers who train 
animals until they learn not to cross over into the dark half before testing the learned 
association (Acevedo, Pfankuch, Ohtsu, & Raber, 2006; Shimamura, Sato, Waguri, 
Uchiyama, et al., 2006), and so the use of more training trials would not be inconsistent 
with other methods used in the literature.  
Alternatively, it is possible that vehicle-treated mice do not display deficiencies in 
PA because the intensity of the footshock used in this experiment created such a strong 
passive avoidance response that it obscured possible differences between the genotypes 
in their ability to withhold responding. This is not to say that rl/rl mice do not have 
deficits in response inhibition, but rather to suggest that the parameters used in the 
current PA test, while effective in producing PA, may not have been effective for 
detecting genotype differences among vehicle-treated animals.  
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Overall, there are three conclusions that can be drawn from the analysis of 
vehicle-treated animals in this experiment. First, genotype differences emerged from OF, 
LD, and PPI testing that are consistent with previous findings by Salinger et al. (2003), 
Groves et al. (2003), and Podhorna and Didriksen (2004). Second, rl/rl mice displayed 
abnormal behaviors on those tests, which make it reasonable to hypothesize that they 
model a human psychopathology such as schizophrenia. Third, current data from NP and 
PA cannot be used to test the hypothesis that rl/rl mice are models of schizophrenia. 
Treatment Validation 
It was also necessary to determine whether risperidone treatment in the present 
experiment was effective enough to test the current hypothesis that the behavioral 
abnormalities of the rl/rl would be improved with the administration of risperidone. At a 
minimum, this means that there should be significant effects of risperidone treatment on 
the behavioral phenotypes of the mice in the present experiments. These effects should be 
evident in a number of behavioral assays and they should be systematic and mutually 
consistent. Table 5 shows a summary of the measures for which there was either a main 
effect of treatment condition or for which treatment condition was part of a significant 
interaction. As can be seen, there were few measures for which there was a significant 
effect of treatment, either alone or in an interaction; in fact, risperidone had a significant 
effect on fewer than one-third of the measures reported here. 
If the dose of risperidone used in this test was adequate, then multiple 
performance measures in the domains of cognition, emotionality, and sensorimotor gating 
should have been significantly affected by risperidone administration. However, only 
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measures related to cognition (habituation of stereotypic movements in OF; task errors, 
repeats, and reference memory in NP) were affected by the drug in this experiment.   
 
Table 5 
Summary of Treatment Condition Results 
________________________________________________________________________ 
 
Test   Measure  Effect  
Open Field Stereotypy Moves Risperidone eliminated existing sex 
differences 
Nose Poke  Reference Memory Some improvement overall with risperidone 
Nose Poke  Errors   rl/rl on risperidone made more errors  
Nose Poke  Repeats  rl/rl on risperidone made more repeats; 
  female rl/rl on risperidone made more 
repeats than female rl/rl on vehicle; female 
+/rl on risperidone made fewer repeats than 
female +/rl on vehicle 
________________________________________________________________________ 
 
 
The small number drug treatment effects seen here could have been Type I errors. 
If these risperidone effects were not merely Type I errors, then the few significant effects 
ought at least to be consistent across measures. Thus, the critical question regarding the 
adequacy of the risperidone dosage becomes: Are the effects of risperidone on 
habituation and in the nose-poke task mutually consistent? In other words, when 
genotype was affected by the drug, was the same genotype always affected, and did the 
drug consistently improve or worsen performance of that genotype? Similarly, when sex 
was differentially affected by the drug, was it always the same sex, and were the effects 
of the drug on that sex consistent across measures? 
 The limitations of the current nose-poke test for testing this experiment’s overall 
hypothesis that rl/rl are models of schizophrenia and that risperidone would improve their 
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deficits have been discussed previously, but those data can still be useful for determining 
the consistency of drug effects, especially since most of the significant drug effects for 
this experiment appeared in this test. There were three NP measures for which there was 
a significant effect of risperidone: reference memory, errors, and repeats. 
Risperidone appears to have had a mildly positive effect on reference memory 
overall. Although animals treated with both risperidone and vehicle showed 
improvements in reference memory over time with both groups performing the same at 
the end of testing, risperidone caused those improvements to begin earlier in training. For 
nose-poke errors, however, rl/rl mice treated with risperidone made more errors for the 
first four days of testing than did all other animals. This effect is consistent with the 
effect of risperidone on rl/rl mice for task repeats; rl/rl mice, especially females, treated 
with risperidone made more repeat entries on the first four days of testing than did all 
other animals. Conversely, female +/rl mice treated with risperidone made fewer repeat 
entries than did female +/rl mice treated with vehicle.  
 Risperidone eliminated existing sex differences for habituation of stereotypies in 
the open field. Throughout the hour-long trial, males and females in both treatment 
conditions showed a decline in the number of stereotypic movements made over time; in 
other words, they both showed habituation to the open field environment. However, in 
the vehicle condition, females showed a relative increase in the number of stereotypies 
made in the last part of the trial (i.e., they showed relatively decreased habituation). In the 
risperidone condition, females did not show this decrease in habituation; they continued 
showing a decline in stereotypies, consistent with the males. For this measure, then, 
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risperidone increased late-stage habituation for females; in other words, it subtly 
improved this measure of primitive learning for female animals.  
The question posed above was, are the effects of risperidone on habituation in the 
open field and in the nose-poke task consistent? That is, when genotype was affected by 
the drug, was the same genotype always affected, and did the drug consistently improve 
or worsen performance of that genotype? Both rl/rl and +/rl mice were affected by the 
drug in some measures. When +/rl mice were affected by risperidone, their behaviors 
improved. When rl/rl mice were affected by the drug, their behaviors worsened. The 
second element of the above question was, when a sex was differentially affected by the 
drug, was it always the same sex, and were the effects of the drug on that sex consistent 
across measures? Females appeared to be more sensitive to effects of risperidone than 
were males.  Hence, when risperidone affected the sexes differentially, it was always the 
females who were affected. Whether the females’ behaviors improved or worsened 
depended on their genotype, consistent with the genotype-specific effects of the drug. 
When female +/rl mice were affected, their behaviors improved, but when female rl/rl 
mice were affected, their behaviors worsened. Thus, it would appear that the significant 
treatment results, though few in number, were at least mutually consistent, and so it 
seems likely that they were not the result of a Type I error but represented a risperidone 
treatment effect instead. 
A review of the literature supports the interpretation that these few significant 
treatment results represent a true finding and not a Type I error. In most studies, 1.0 
mg/kg was the highest dosage of risperidone used, and was effective at altering various 
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behaviors, such as freezing in contextual fear conditioning (Miyamoto, Tsuji, Takeda, 
Ohzeki, et al., 2004); vacuous chewing (Carvalho, Silva, Abilio, Barbosa, et al., 2003); 
PPI (Olivier, Leahy, Mullen, Paylor, et al., 2001); and marble burying in anxiety studies 
(Li, Morrow, & Witkin, 2006; Matsushita, Egashira, Harada, Okuno, et al., 2005). In the 
study by Carvalho et al. (2003), even doses as low as 0.1 mg/kg affected vacuous 
chewing movements. In the other studies listed above, no dose higher than 1.0 mg/kg was 
used and yet all detected effects of risperidone treatment on behaviors of interest here. 
Thus, from the literature it seems that the dose used in the current study should have been 
adequate to affect a range of behavioral characteristics in the cognitive, emotional, and 
sensorimotor gating domains and to do so in a systematic, consistent fashion.  Hence, the 
literature suggests that the dose of risperidone used here is the maximal dose that would 
be experimentally appropriate.  Moreover, in this literature, behaviors other than those 
reported here are sensitive to the dose of risperidone used here; in the case of some 
behaviors, doses only 10% of those used here were effective at altering behavior. This is 
consistent with the view that the sparse behavioral effects of risperidone treatment 
reported here are not the result of type I errors occurring in a background of insufficient 
risperidone dosing. At the same time the literature indicates that the dose of risperidone 
used here should not only be effective but also should have produced a wider array of 
behavioral effects than those observed in the present study. Perhaps, however, the strain 
used here (C6B3), which a search of the literature indicates has never been tested with 
risperidone, is less sensitive to risperidone or metabolizes it more rapidly than did the 
mice used in the studies cited. However, the studies by Costa and colleagues (Costa et al., 
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2002; Tremolizzo et al., 2002; Carboni et al., 2004) examined drug effects on +/rl mice 
from the same background strain as those used here and found significant effects of the 
drugs. If those results are true, then it suggests that +/rl mice, at least, are not 
hyporesponsive to drugs, and so, unless a complete lack of reelin reduces drug efficacy, 
rl/rl mice also should not be hyporesponsive. Thus, it does seem that the sparse drug 
effects are a true finding and not a Type I error.   
Implications and Directions for Future Research 
 So what do these results suggest? First, the genotype differences found in Salinger 
et al. (2003) were supported, both for the rl/rl and for the +/rl, and supported the findings 
by Groves et al. (2003), Salinger et al. (2003), and Podhorna and Didriksen (2004) that 
the +/rl is behaviorally indistinguishable from the +/+.  Second, because risperidone 
produced very few effects on the rl/rl, and because the few existing effects worsened the 
rl/rl’s performance instead of improving it as predicted, the conclusion to be drawn from 
this experiment is that rl/rl mice do not model schizophrenia. However, it is possible that 
rl/rl mice model another human disorder, such as one that is not consistently responsive 
to risperidone. The behavioral abnormalities found in rl/rl mice, including deficits in PPI, 
cognition, and emotionality, are not unique to schizophrenia and are found in other 
pathologies as well, especially those related to executive functioning. 
The rl/rl mice display hyperactivity in the open field as well as other behaviors 
that could be explained as executive functioning deficits, such as impulsivity (for 
example, their apparent inability to cease movement toward a more dominant mouse in 
the social dominance task and their faster approach to novel objects than other genotypes, 
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reported in Salinger et al., 2003). Therefore, one disorder that rl/rl mice could model is 
Attention Deficit/Hyperactivity Disorder (AD/HD), as hyperactivity and impulsivity are 
two of the core symptoms for a diagnosis of AD/HD (DSM-IV-TR). The hypothesis that 
rl/rl mice may model AD/HD has been tested in our laboratory by using four different 
doses of methylphenidate on rl/rl, +/+, and +/rl mice, and the data from that experiment 
are currently being analyzed and interpreted. To date, it is unknown whether these results 
support or refute this hypothesis. 
 Another possible disorder that the rl/rl could model is autism. Some of the 
symptoms of autism include impairment in social interaction, impairments in 
communication, and the presence of repetitive, stereotyped behavior (DSM-IV-TR). 
Interestingly, autism was at one time often confused with childhood-onset schizophrenia 
(Asarnow & Asarnow, 2003), and also shares many overlapping symptoms with AD/HD; 
in fact, there commonly is such a high frequency of overlap between symptomatology in 
AD/HD and autism that clinicians are directed to generate a primary diagnosis of autism 
rather than of AD/HD or of autism with comorbid AD/HD when symptoms consistent 
with both are present (King & Bostic, 2006). Recently, a study has suggested that 
sensorimotor gating deficiencies may be present in adults with autism as well (Perry, 
Minassian, Lopez, Maron, & Lincoln, 2006), although there is very little published 
literature on the subject. Thus, many of the behavioral abnormalities of the rl/rl that have 
been hypothesized to model schizophrenia and/or AD/HD might actually model autism 
instead, since deficient executive function, emotionality, cognitive dysfunction, and 
stereotypy (all of which are found in the rl/rl) are also found in people with autism 
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(Klinger, Dawson, & Renner, 2003).  
  There is also evidence that reelin irregularities are associated with autism and 
autism spectrum disorders, not just with schizophrenia. A post-mortem study found that, 
compared to control brains, brains of autistic individuals were found to have decreased 
levels of both processed and unprocessed reelin in the cerebellum (Fatemi, Stary, Halt, & 
Realmuto, 2001), and genetic studies have found an association between autism and 
several reelin gene variants in humans (Persico, D’Agruma, Maiorano, Totaro, et al., 
2001; Serajee, Zhong, & Mahbubul Huq, 2006; Skaar, Shao, Haines, Stenger, et al., 
2005). There are also several shared brain abnormalities common to people with autism 
(Bauman, 1991; Courchesne, 1997) and rl/rl mice (Goffinet, 1984), including decreased 
Purkinje cell numbers as well as cytoarchitectonic abnormalities in the hippocampus, 
amygdala, and entorhinal cortex, although humans with autism do not display the 
inverted laminae of the cortex associated with the rl/rl brain (Persico et al., 2001).  
Medicinal treatment of autism is fairly difficult, and medications are typically 
prescribed in order to control symptoms instead of to treat the disease itself (Tuchman, 
2004). According to King and Bostic (2006, p. 163), “virtually every psychotropic 
medication available has been examined in patients who have [autism spectrum 
disorders],” but none of them specifically treats autism or has FDA approval to do so. 
Thus, if rl/rl mice modeled autism rather than schizophrenia, risperidone would not be 
expected to produce reliable, large effects, consistent with the findings reported here. 
Accordingly, it would be difficult to test the hypothesis that rl/rl mice are models of 
autism by using an antipsychotic or another type of drug.  
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Crawley (2004), however, has hypothesized that there are many behavioral tests 
that can measure autistic-like behaviors in mice that might address the possibility that 
rl/rl mice model autism or autism spectrum disorder, rather than schizophrenia. For 
example, the social recognition task measures a mouse’s preference (or lack thereof) to 
investigate a stranger conspecific versus a novel, inanimate object. Normal animals 
would spend more time sniffing and otherwise investigating another mouse than they 
would spend investigating a novel inanimate object. An animal thought to model autism, 
however, would not be expected to show this preference because of the autistic symptom 
of inappropriate social interactions. Similarly, social communication can be measured in 
mice through responses to social olfactory cues and parental responses to pup ultrasonic 
vocalizations.  
Therefore, one way to begin testing the hypothesis that rl/rl model autism would 
be to observe their behaviors on a battery of social interaction measures, for which there 
are currently no published data; to date, the only such test in which rl/rl have been 
analyzed was the social dominance task in Salinger et al (2003). Currently, our lab is 
investigating differential genotype responding in the social recognition task, but those 
results have not yet been analyzed. Thus, there is a need for a more extensive social 
phenotype of the rl/rl to be determined in order to conclude that the rl/rl models autism. 
Conclusions 
 Risperidone, in the dosage used here, produced an unexpectedly limited number 
of statistically significant effects a variety of behavioral assays.  Moreover, assuming 
those significant effects were not the result of type I errors, they influenced the behavior 
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of rl/rl mice in a direction that was the opposite of that needed to confirm the prediction 
that, as good models for schizophrenia, rl/rl mice would show improvements in 
cognition, emotionality, and sensorimotor gating due to risperidone. Although the rl/rl 
exhibits several behavioral abnormalities consistent with a schizophrenia-like pathology, 
those same deficits can be found in other disorders as well. Future research should 
examine the hypothesis that rl/rl mice model autism by analyzing their behavior on a 
wider variety of social measures. 
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